

HE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE: PRESENTS: SHALL COME?

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

November 02, 2017

THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE RECORDS OF THIS OFFICE OF THE FILE WRAPPER AND CONTENTS OF:

APPLICATION NUMBER: 08/233,166 FILING DATE: April 26, 1994

> By Authority of the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office



SYLVIA HOLLEY Certifying Officer

> ASTELLAS 2006 Sawai v. Astellas IPR2018-00079

Class 5	िंगे	Line .
SERIAL 18, 233166		NTENT JMBER
SERIAL NUMBER FILING 08/233,166 04/26	a DATE CLASS 194 514 514 SUBCLASS 304 304	t GROUP ART UNIT EXAMINER 357 1201 3 Northington - Davis
MICHOEL N. FISHER	ANN E. WEBER, SCUTCH PLA	ISON, NJ; ELIZABETH M, NAYLOR, NS, NJ.
MICHOEL N. FISHER SCOTCH PLAINS, NJ; **CONTINUING DATA- VERTFIED 	**************************************	
FOREIGN/PC1 APPL	NON C . ICATIONS ********	
PERSONAL PROPERTY AND ADDRESS OF A DESCRIPTION OF A DESCR		
	ENSE GRANTED 05/20/94	INDEP. FILING FEE ATTORNEY'S
Artified and Asknowledged Akamilies MOLLZE M. YANG PATENT DEPT.	AS STATE OR SHEETS TOTA COUNTRY DRWGS. CLAI	INDEP. FILING FEE ATTORNEY'S DOCKET NO. 16 1 #710.00 19203
Artified and Asknowledged Framilier MOLLIE M. YANG PATENT DFPT. MERCK & CO., INC. P.O. BUX 2000 RAHWAY, NJ 07065	AS STATE OR SHEETS TOTA COUNTRY DRWGS CLAI	MS CLAIMS RECEIVED DOCKET NO. 16 1 #710.00 19203
Vertiled and Asknowledged Remined MOLLIE M. YANG PATENT DEPT. MERCK & CO., INC. P.G. BOX ZOOU RAHMAY, NJ 07963	AS FLED NJ 0	MS CLAIMS RECEIVED DOCKET NO. 16 1 #710.00 19203
Vertiled and Asknowledged Remined 4402LIE M. YANG PATENT DEPT. MERCK & CO., INC. P.G. BOX ZOOU RAHMAY, NJ 07963	AS FLED NJ 0	AGONISIS FOR THE DEPT of COMMPat & TM ORICE-PTO-436L (rev. 10-78)
Percisin priority disined 35 USC 118 conditions met yes Vertified and Acknowledged Transfer MOLLZE M. YANG PATENT DEPT. MERCK & SU., INC. P.O. BUX ZOOU RAHWAY, NJ 07063 SUBSTITUTED SULFOR TREATMENT DE DIABLE PARTS OF APPLICATION FILED SEPARATELY NOTICE OF ALLOWANGE MAILED 3/27145	AS FILED STATE OF SHEETS TOTA STITUTATE -9907 VAMIDES AS SELECTIVE DETAGE ETES AND OBESITY US ZUMA N. DAVIS Assistant Examiner	AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) Applications Examiner 3-27-95- CLAIMS ALLOWED Total Charms Print Claim
Pertiled and Advice and Links	AS FILED STATE OF SHEETS TOTA STITUTATE -9907 VAMIDES AS SELECTIVE DETAGE ETES AND OBESITY US ZUMA N. DAVIS Assistant Examiner	AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) Applications Examiner 3-27-95- CLAIMS ALLOWED Total Charms Print Claim
PARTS OF APPLICATION FILED SEPARATELY NOTICE OF ALLOWANGE MAILEL 3/27145 Label	AS FLED STATE OF SHEETS TOTAL STATE OF SHEETS TOTAL NJ 0 199407 14MIDES AS SELECTIVE DETAS TES AND OBESITY US 2 2 2 2 2 2 2 2 2 2 2 2 2	AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) AGONISIS FOR THE DEPT of COMMPat. & TM Office-PTO-436L (rev. 10-78) Applications Examiner 3-27-95- CLAIMS ALLOWED Total Charms Print Claim
PARTS OF APPLICATION FILED SEPARATELY MOTICE OF ALLOWANCE MAILED 3/27145 BISUE FEE Amount Due BISUE FEE Amount Due BISUE FEE	AS FLEED STATE OF BREETS TOTAL NO OF COUNTRY DRWGS TOTAL NO OF COUNTRY DRWGS TOTAL OF COUNTRY DRWGS	AGONISTS FOR THE AGONISTS FOR THE DEPT of COMM-Pat & TH Office-PTO-436L (rev. 10-78) CLAIMS ALLOWED Total Chams Print Claim DRAWING Sheets Drive, Figs. Drive, Print, Fig. ISSUE BATCH 09


			U.S. PATENT APPLICATION			
ERIAL NUMBER	2.011	FI	LING DATE	CLASS	GROUP ART UNIT	
08/233,166			14/26/94	514	1205	
SCOTCH PL		ANN E. WEE	SER, SCOTCH PLA		ZABETH M. NAYLOR,	
VERIFIED)					
FORBIGN VERIFIED	/PCT APPLI	CATIONS	***			
	-					
			ED 05/23/94			
TATEOR	FILING LICE SHEETS DRAWING	NSE GRANT TOTAL CLAIMS	ED 05/23/94	FILING FEE RECEIVED	ATTORNEY DOCKET NO.	
TATEOR	SHEETS	TOTAL	INDEPENDENT	FILING FEE RECEIVED \$710.00	ATTORNEY DOCKET NO. 19203	
TATE OR OUNTRY NJ MOLLIE N	SHEETS DRAWING D	TOTAL CLAIMS	INDEPENDENT	RECEIVED		
NJ	SHEETS DRAWING 0 4. YANG DEPT. CO., INC.	TOTAL CLAIMS	INDEPENDENT	RECEIVED	19203	
MOLLIE M MOLLIE M PATENT I MERCK & P.O. BOJ	SHEETS DRAWING 0 4. YANG DEPT. CO., INC.	TOTAL CLAIMS 16	INDEPENDENT	RECEIVED		
MOLLIE M MOLLIE M PATENT I MERCK & P.O. BOJ RAHWAY,	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065-	TOTAL CLAIMS 16 0907	INDEPENDENT CLAIMS 1	RECEIVED \$710.00	19203	
MOLLIE M MOLLIE M PATENT I MERCK & P.O. BOJ RAHWAY,	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065-	TOTAL CLAIMS 16 0907 AMIDES AS	INDEPENDENT CLAIMS 1 SELECTIVE BET	RECEIVED \$710.00	19203	
MOLLIE M MOLLIE M PATENT I MERCK & P.O. BOJ RAHWAY,	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065- UTED SULFON	TOTAL CLAIMS 16 0907 AMIDES AS	INDEPENDENT CLAIMS 1 SELECTIVE BET	RECEIVED \$710.00	19203 PR THE	
ATE OR OUNTRY NJ MOLLIE M PATENT I MERCK & P.O. BOJ RAHWAY, SUBSTITU	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065- UTED SULFON WT OF DIABE	TOTAL CLAIMS 16 0907 AMIDES AS TES AND O	INDEPENDENT CLAIMS 1 SELECTIVE BETA BESITY	RECEIVED \$710.00 A3 AGONISTS FO	19203 PR THE	
TATE OR OUNTRY NJ MOLLIE N PATENT I MERCK & P.O. BOJ RAHWAY, SUBSTITU TREATMEN	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065- UTED SULFON WT OF DIABE	10TAL CLAIMS 16 0907 AMIDES AS TES AND O	INDEPENDENT CLAIMS 1 SELECTIVE BET BESITY true copy from the cation which is iden	RECEIVED \$710.00 A3 AGONISTS FO	19203 PR THE	
MOLLIE M MOLLIE M MOLLIE M MERCK & P.O. BOJ RAHWAY, SUBSTITU TREATMEN	SHEETS DRAWING 0 4. YANG DEPT. CO., INC. K 2000 NJ 07065- UTED SULFON WT OF DIABE	10TAL CLAIMS 16 0907 AMIDES AS TES AND O	INDEPENDENT CLAIMS 1 SELECTIVE BET BESITY true copy from the cation which is iden	RECEIVED \$710.00 A3 AGONISTS FO	19203 PR THE	

.

18/233166

PATENT APPLICATION SERIAL NO.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET



•

Page 4 of 108







TITLE OF THE INVENTION SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

-1-

5

10

15

BACKGROUND OF THE INVENTION

 β -Adrenoceptors have been subclassified as β_1 and β_2 since 1967. Increased heart rate is the primary consequence of β_1 -receptor stimulation, while bronchodilation and smooth muscle relaxation typically result from β_2 stimulation. Adipocyte lipolysis was initially thought to be solely a β_1 -mediated process. However, more recent results indicate that the receptor-mediating lipolysis is atypical in nature. These atypical receptors, later called β_3 -adrenoceptors, are found on the cell surface of both white and brown adipocytes where their stimulation promotes both lipolysis (breakdown of fat) and energy expenditure.

Early developments in this area produced compounds with greater agonist activity for the stimulation of lipolysis (β 3 activity) than for stimulation of atrial rate (β 1) and tracheal relaxation (β 2). These early developments disclosed in Ainsworth <u>et al.</u>, U.S. Patents 4,478,849 and 4,396,627, were derivatives of phenylethanolamines.

Such selectivity for β_3 -adrenoceptors could make compounds of this type potentially useful as antiobesity agents. In addition, these compounds have been reported to show antihyperglycemic effects in animal models of non-insulin-dependent diabetes mellitus.

A major drawback in treatment of chronic diseases with β_3 agonists is the potential for stimulation of other β -receptors and subsequent side effects. The most likely of these include muscle tremor (β_2) and increased heart rate (β_1). Although these phenylethanolamine derivatives do possess some β_3 selectivity, side effects of this type have been observed in human volunteers. It is reasonable to expect that these side effects resulted from partial β_1 and/or β_2 agonism.

More recent developments in this area are disclosed in Ainsworth et al., U.S. Patent 5,153,210, Caulkett et al., U.S. Patent

Chechado Chechado Chechado



Clecked

4,999,377, Alig et al., U.S. Patent 5,017,619, Lecount et al., European Patent 427480 and Bloom et al., European Patent 455006.

Even though these more recent developments purport to describe compounds with greater β_3 selectivity over the β_1 and β_2 activities, this selectivity was determined using rodents, in particular, rats as the test animal. Because even the most highly selective compounds, as determined by these assays, still show signs of side effects due to residual β_1 and β_2 agonist activity when the compounds are tested in humans, it has become apparent that the rodent is not a good model for predicting human β_3 selectivity.

Recently, assays have been developed which more accurately predict the effects that can be expected in humans. These assays utilize cloned human β_3 receptors which have been expressed in Chinese hamster ovary cells. See Emorine et al, <u>Science</u>, 1989.

245:1118-1121; and Liggett, <u>Mol. Pharmacol.</u>, 1992, 42:634-637. The agonist and antagonist effects of the various compounds on the cultivated cells provide an indication of the antiobesity and antidiabetic effects of the compounds in humans.

²⁰ <u>SUMMARY OF THE INVENTION</u>

The instant invention is concerned with substituted sulfonamides which are useful as antiobesity and antidiabetic compounds. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the substituted sulfonamides. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.

30

25

DESCRIPTION OF THE INVENTION

The present invention provides compounds having the formula I:

10


5



where



- 3 -



	n is	0 to 5;
10	m is	0 or 1;
	r is	0 to 3;
	A is	phenyl, a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, a benzene ring fused to a C3-C8 cycloalkyl ring,
15		a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, or a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered
20		heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen;
	R ¹ is	hydroxy, oxo, halogen, cyano, NR ⁸ R ⁸ , SR ₈ trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, SO2R ⁹ , OCOR ⁹ , NR ⁸ COR ⁹ , COR ⁹ , NR ⁸ SO2R ⁹ , NR ⁸ CO2R ⁸ , or
25		C1-C6 alkyl substituted by hydroxy, halogen, cyano, NR ⁸ R ⁸ , SR ⁸ , trifluoromethyl, C1-C6 alkoxy, C3-C8 cycloalkyl, phenyl, NR ⁸ COR ⁹ , COR ⁹ , SO ₂ R ⁹ , OCOR ⁹ , NR ⁸ SO ₂ R ⁹ or NR ⁸ CO ₂ R ⁸ ;
	R2 and R3	are independently hydrogen, C1-C6 alkyl or C1-C6 alkyl
30		with 1 to 3 substituents selected from hydroxy, C1-C6 alkoxy, and halogen;
	X is	-CH2-, -CH2-CH2-, -CH=CH- or -CH2O-;
	R4 and R5	are independently hydrogen, C1-C6 alkyl, halogen, NHR ⁸ , OR ⁸ , SO2R ⁹ or NHSO2R ⁹ ;

R6 is hydrogen or C1-C6 alkyl;

R7 is	$Z_{-}(R^{1a})_{n};$
R ^{1a} is	R1, C3-C8 cycloalkyl, phenyl, or 5 or 6-membered
	heterocycle with from 1 to 3 heteroatoms selected from
	oxygen, sulfur and nitrogen, optionally substituted with up
	to three groups independently selected from oxo, R ⁸ and NR ⁸ R ⁸ ;
Z is	phenyl, naphthyl, a 5 or 6-membered heterocyclic ring
2.15	with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, a benzene ring fused to a C3-C8 cycloalkyl
	ring, a benzene ring fused to a 5 or 6-membered
	heterocyclic ring with from 1 to 3 heteroatoms selected
	from oxygen, sulfur and nitrogen, or a 5 or 6-membered
	heterocyclic ring with from 1 to 3 heteroatoms selected
	from oxygen, sulfur and nitrogen fused to a 5 or 6-
	membered heterocyclic ring with from 1 to 3 heteroatoms
DO :	selected from oxygen, sulfur and nitrogen;
R8 is	hydrogen, C1-C10 alkyl, C3-C8 cycloalkyl, Z optionally
	having 1 to 3 substituents selected from halogen, C1-C6
	alkyl and C1-C6 alkoxy, or C1-C10 alkyl having 1 to 3
	substituents selected from hydroxy, halogen, CO2H, CO2-
	C1-C6 alkyl, SO2-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6
	alkoxy, and Z optionally substituted by from 1 to 3 of
	halogen, C1-C6 alkyl or C1-C6 alkoxy;
R ⁹ is	R8 or NR8R8; or
a pharma	centically acceptable salt thereof

- 4 -

a pharmaceutically acceptable salt thereof.

Preferred compounds of the instant invention are realized when in the above structural formula I:

R² and R³ are hydrogen or methyl;

X is	-CH2-;
n is	0 to 3;
m is	1;
r is	0 to 2; and
R4, R5 ;	and R6 are hydrogen.

5

10

15

20

25





Other preferred compounds of the instant invention are realized when in the above structural formula I:

- 5 -

A is phenyl or a 6-membered heterocyclic ring with 1 or 2 nitrogen atoms;

R1 is

hydroxy, halogen, cyano, trifluoromethyl, NR8R8, NR8SO2R9, NR8COR9, NR8CO2R8, C1-C6 alkyl optionally substituted by hydroxy; and 0 or 2.


r is

More preferred compounds are represented by the formula

10 Ia:

15


5



Ia

1212	wherein	
20	n is	0 to 3;
	m is	1
	R ¹ is	halogen or NR ⁸ R ⁸ ;
	Rla is	halogen, C1-C6 alkyl, NR ⁸ R ⁸ , NR ⁸ COR ⁹ , NR ⁸ CO ₂ R ⁸ ,
20120		OCOR ⁹ , or 5 or 6-membered heterocycle with from 1 to 3
25		heteroatoms selected from oxygen, sulfur and nitrogen,
		optionally substituted with up to three groups independently selected from oxo, R ⁸ and NR ⁸ R ⁸ ;
	Z is	phenyl, naphthyl or benzene ring fused to a 5 or 6-
		membered heterocyclic ring with from 1 to 3 heteroatoms
30		selected from oxygen, sulfur and nitrogen;
	X is	-CH2-; and
	\mathbb{R}^2 , \mathbb{R}^3 ar	e independently hydrogen or methyl.
		Other more preferred compounds are represented by
	formula I	b:





5

Τb

	wherein			
10	n is	0 to 3;		
	m is	1		
	R ¹ is	hydroxy, NR ⁸ R ⁸ or halogen;		
	R ^{1a} is	halogen, C1-C6 alkyl, NR ⁸ R ⁸ , NR ⁸ COR ⁹ , NR ⁸ CO ₂ R ⁸ ,		
		OCOR ⁹ , or 5 or 6-membered heterocycle with from 1 to 3		
15		heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to three groups independently selected from oxo, R^8 and NR^8R^8 ;		
	Z is	phenyl, naphthyl or benzene ring fused to a 5 or 6-		
		membered heterocyclic ring with from 1 to 3 heteroatoms		
20		selected from oxygen, sulfur and nitrogen;		
20	X is	-CH2-; and		
	\mathbb{R}^2 and \mathbb{R}^3 are independently hydrogen or methyl.			
		Representative antiobesity and antidiabetic compounds of		
	the present invention include the following:			
25		2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]- ninocarbonylamino)benzenesulfonamide		
	N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-			
	4-iodobenz	enesulfonamide		
	N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino[ethyl]phenyl]-			
30	benzenesulfonamide			
30	N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-			
	2-naphthal	enesulfonamide		
	<u>N</u> -[4-[2-[[2	N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl])ethyl]amino]ethyl]phenyl]-		
3-quinolinesulfonamide				

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-</u> 5-benzisoxazolesulfonamide

- 7 -

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]</u>-4-[(hexylmethylaminocarbonyl)amino]benzenesulfonamide

5

N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[(dimethylaminocarbonyl)amino]benzenesulfonamide N-[4-[2-[]2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-

4-(3-hexyl-2-imidazolidon-1-yl)benzenesulfonamide

N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-

 10 (hexylaminocarbonylamino)benzenesulfonamide <u>N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-</u> isopropylbenzenesulfonamide

N-[4-]2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-2-naphthalenesulfonamide

15 <u>N</u>-[4-[2-][2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3quinolinesulfonamide

<u>N-[4-]2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-</u> [(hexylmethylaminocarbonyl)amino]benzenesulfonamide

20 <u>N-[4-[2-[]2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl[phenyl]-4-(3-hexyl-2-imidazolidon-1-yl]benzenesulfonamide</u>

<u>N-[4-[2-{[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-</u> iodobenzenesulfonamide

<u>N-[4-]2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-4-iodobenzenesulfonamide</u>

25 <u>N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-2-naphthalenesulfonamide</u>

N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-3quinolinesulfonamide

<u>N</u>-[4-[2-][2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]propyl] phenyl]-4-(hexylaminocarbonylamino)benzenesulfonamide
 <u>N</u>-[4-[2-][2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]propyl] phenyl]-4-iodobenzenesulfonamide
 <u>N</u>-[4-[2-][2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]propyl]-

phenyl|benzenesulfonamide

- 8 -

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl])ethyl]amino]propyl]</u>phenyl]-2-naphthalenesulfonamide

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]propyl]</u>phenyl]-3-quinolinesulfonamide

N-[4-[2-[[2-hydroxy-2-(3-chlorophenyl)ethyl]amino]ethyl]phenyl]-3isopropylbenzenesulfonamide


N-[4-[2-[[2-hydroxy-2-(3-chlorophenyl)ethyl]amino]ethyl]phenyl]-2-naphthalenesulfonamide

¹⁰ <u>N-[4-[2-[[2-hydroxy-2-(3-chlorophenyl])ethyl]amino]ethyl]phenyl]-3-</u> quinolinesulfonamide

The compounds of the instant invention all have at least one asymmetric center as noted by the asterisk in structural Formula I. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule,

- - Formula I, it has been found that the compound in which the hydroxy substituent is above the plane of the structure, as seen in Formula Ic, is more active and thus more preferred over the compound in which the hydroxy substituent is below the plane of the structure.

The following stereospecific structure represents the preferred stereoisomers of the instant invention:



Ic

25

- 9 -

where n, m, r, A, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and X are as defined above under formula I.

Throughout the instant application, the following terms have the indicated meanings:

The alkyl groups specified above are intended to include those alkyl groups of the designated length in either a straight or branched configuration. Exemplary of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tertiary butyl, pentyl, isopentyl, hexyl, isohexyl, and the like.

The alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a straight or branched configuration. Exemplary of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.

The term "halogen" is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.

Examples of 5 and 6-membered heterocycles and fused heterocycles of A, Z and R^{1a} include pyridyl, quinolinyl, pyrimidinyl, pyrrolyl, thienyl, imidazolyl, thiazolyl, benzimidazolyl, thiadiazolyl, benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, tetrahydronaphthyl, dihydrobenzofuranyl, tetrahydroquinolinyl, furopyridine and thienopyridine.

The preferred values of A and Z are phenyl, naphthyl or heterocycles with from 1 to 4 heteroatoms independently selected from one of oxygen or sulfur, and/or 1 to 4 nitrogen atoms.

The more preferred values of A are phenyl, pyridyl, quinolinyl, pyrimidinyl, pyrrolyl, thienyl, imidazolyl, and thiazolyl.

The more preferred values of Z are phenyl, naphthyl, quinolinyl, thienyl, benzimidazolyl, thiadiazolyl, benzothiadiazolyl, indolyl, indolinyl, benzodioxolyl, benzodioxanyl, benzothiophenyl, benzofuranyl, benzoxazinyl, benzisoxazolyl, benzothiazolyl, tetrahydronaphthyl, dihydrobenzofuranyl, and tetrahydroquinolinyl.

10

5

.

15

20

25





- 10 -

Certain of the above defined terms may occur more than once in the above formula and upon such occurrence each term shall be defined independently of the other; thus for example, NR⁸R⁸ may represent NH2, NHCH3, N(CH3)CH2CH3, and the like.

The following abbreviations are used throughout the specification:


	Boc	: tert-butyloxycarbonyl
	Cbz	: carbobenzyloxy
	DIP-Cl	: diisopinocampheylchloroborane
10	DMF	: dimethylformamide
	DMSO	: dimethylsulfoxide
	HPLC	: high pressure liquid chromatography
	Me	: methyl
	MPLC	: medium pressure liquid chromatography
15	Ms	: methanesulfonyl (mesyl)
	NBS	: N-bromosuccinimide
	NCS	: N-chlorosuccinimide
	nHex	; n-hexyl
	TFA	: trifluoroacetic acid
20	THF	: tetrahydrofuran
	The	compounds (I) of the present invention can be

prepared from epoxide intermediates such as those of formula II and amine intermediates such as those of formula III. The preparation of these intermediates is described in the following schemes.

25

30

5



where n, m, r, A, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and X are as defined above.

Compounds II are known in the literature or may be conveniently prepared by a variety of methods familiar to those skilled in the art. One common route is illustrated in Scheme 1. Acid chloride $\underline{1}$, which may be commercially available or readily prepared from the corresponding acid by treatment with, for example, thionyl chloride or oxalyl chloride, is treated with diazomethane in a solvent such as diethyl ether. The resultant diazoketone is then treated with hydrogen chloride to give chloroketone $\underline{2}$ (X = Ci). The haloketone $\underline{2}$ is then reduced with a reducing agent such as sodium borohydride. The resultant alcohol $\underline{3}$ is treated with base such as potassium carbonate in refluxing acetone to provide the desired epoxide II. The enantiomerically enriched (*R*) and (*S*) epoxides II are readily available by asymmetric reduction of haloketones $\underline{2}$ using chiral reducing agents such as (-) or (+)-DIP-Cl, (*R*) or (*S*)-Alpine borane or (*R*) or (*S*)-tetrahydro-1-methyl-3,3-


15 diphenyl-1H,3H-pyrrolo[1,2-c][1,3,2]oxazaborole-borane ((R) or (S)-OAB•BH₃).

20

5

10

25



20

Π

An alternate route to the desired haloketones 2 is illustrated in Scheme 2. Methylketone 4 may be converted to the corresponding haloketone using a variety of reagents known to those in the art and summarized in Larock Comprehensive Organic Transformations; VCH: New York, 1989, 369-372. Conveniently, methylketone 4 is treated with chlorine or N-chlorosuccinimide in acetic acid with an additional acid source such as hydrogen chloride or aluminum chloride. For the

30

synthesis of 2 (X = Br), bromine or NBS with hydrogen bromide or aluminum bromide may be used. In some cases, the chloro or bromoketones 2 may be commercially available.

$\frac{SCHEME 2}{(R^{1})_{n}}$ $(R^{1})_{n}$ $(R^{1})_{n}$ $(R^{1})_{n}$ $(R^{1})_{n}$ $(R^{1})_{n}$ $(R^{1})_{n}$ $(R^{1})_{n}$ (X = CI, Br)

- 13 -

10

15

5

Many of the methylketones <u>4</u> are commercially available or readily prepared by methods described in the literature and known to those skilled in the art. R¹ substituents on the acid chlorides <u>1</u> or methylketones <u>4</u> may need to be protected during the subsequent procedures. A description of such protecting groups may be found in: <u>Protective Groups in Organic Synthesis</u>, 2nd Ed., T. W. Greene and P. G. M. Wuts, John Wiley and Sons, New York, 1991.


Compounds III can be conveniently prepared by a variety
of methods familiar to those skilled in the art. A convenient route for
their preparation when R6 is hydrogen is illustrated in Scheme 3.
Compound 5 is selectively protected as a suitable carbamate derivative 6 with, for example, di-*tert*-butyl dicarbonate or carbobenzyloxy
chloride. This compound is then treated with a sulfonyl halide,
preferably the sulfonyl chloride 7, and a base such as pyridine in an
anhydrous solvent such as dichloromethane or chloroform for 0.5 to 24 hours at temperatures of -20 to 50°C, preferably 0°C, to provide the sulfonamide 8. The protecting group is then removed with, for example, trifluoracetic acid in the case of Boc or catalytic hydrogenation in the case of Cbz, to give the desired amine 9.

30



- 14 -

SCHEME 3.




Compounds III where R^6 is not hydrogen may be conveniently prepared as illustrated in Scheme 4. Sulfonamide <u>8</u>, prepared as described above, is alkylated with an appropriate alkylating agent <u>10</u> in the presence of base to provide sulfonamide <u>11</u>. Removal of the protecting group as above gives the desired compound <u>9a</u>.

30



- 15 -

SCHEME 4



20

25

The sulfonyl chlorides Z, many of which are commercially available, can also be readily prepared by a number of methods familiar to those skilled in the art. One suitable method involves the addition of an organolithium reagent or a Grignard reagent to sulfuryl chloride following the procedure of S. N. Bhattacharya, <u>et. al.</u>, J. Chem. Soc. (C), 1265-1267 (1969). Another convenient method involves the treatment of a thiol with sulfuryl chloride and a metal nitrate according to the procedure of Y. J. Park, <u>et. al.</u>, Chemistry Letters, 1483-1486 (1992). Sulfonic acids are also conveniently converted to the corresponding sulforyl chloride by treatment is 10 p.

 corresponding sulfonyl chloride by treatment with PCI5, PCI3 or SOCI2
 (J. March, <u>Advanced Organic Chemistry</u>, 4th Ed., John Wiley and Sons, New York: 1992, p1297 and references sited therein). Aromatic and heteroaromatic compounds may be chlorosulfonylated directly by treatment with Vilsmeier's reagent or chorosulfonic acid (Organic Synthesis, I, 8).

- 16 -

19203

The diamines $\underline{5}$ are commercially available or readily prepared by methods described in the literature or known to those skilled in the art. Compound $\underline{5}$ where R² or R³ is methyl can be prepared from the corresponding amino acid following the method of J. D. Bloom, <u>et. al.</u>, J. Med. Chem., <u>35</u>, 3081-3084 (1992). As illustrated in Scheme 5 for R³ = methyl, the appropriate (*R*) amino acid <u>12</u> is esterified, conveniently by treatment with methanolic hydrochloric acid, and then treated with di-*tert*-butyl dicarbonate to give compound <u>13</u>. The ester group is reduced with a hydride source such as lithium borohydride and the resultant alcohol is converted to a leaving group such as a mesylate. Removal of the Boc protecting groups gives diamine <u>14</u>. This compound is subjected to catalytic hydrogenation in the presence of base such as sodium acetate to give the desired α -methyl amine <u>15</u>. The other enantiomer is available through an analogous sequence starting with the corresponding (*S*) amino acid.

20

15

5

10

25




SCHEME 5


5

10

15


.





2) MeSO₂Cl, Et₃N 3) TFA, CH₂Cl₂ H₂, NaOAc

1) LIBH



cat. Pd

Me 15

25

30

20

Diamines 5 or sulfonamide amines 9 where X is -CH₂Oand m is 1 are also readily prepared by methods described in the literature or known to those skilled in the art. For example, as shown in Scheme 6, the sodium salt of 4-nitrophenol <u>16</u> is alkylated with 1bromo-2-chloroethane, conveninetly in refluxing 2-butanone with a base such as potassium carbonate to give chloro derivative <u>17</u>. The chloride is converted to the corresponding amine by treatment with lithium azide followed by reduction with, for example, triphenylphosphine in aqueous tetrahydrofuran. Protection of the resultant amine, conveniently as its t-butyl carbamate by treatment with di-<u>tert</u>-butyldicarbonate, gives derivative <u>18</u>. The nitro group is then reduced, for example, by

19203




÷



catalytic hydrogenation to provide amine <u>19</u>. Acylation of intermediate <u>19</u> with sulfonyl chloride <u>7</u>, sollowed by deprotection with acid such as trifluoroacetic acid gives the desired intermediate <u>20</u>.

- 18 -




Alternatively, diamine 5 where X is -CH₂O- and m is 1 is available from intermediate 19 by treatment with trifluoroacetic acid. This diamine may then be modified as illustrated in Scheme 3.

Diamines 5 and sulfonamide amines 9 where X is -CH2CH2- and m is 1 are also readily prepared by methods described in the literature or known to those skilled in the art. For example, as shown in Scheme 7, bromo derivative 21 is treated with sodium cyanide to provide nitrile 22. The nitro group is selectively reduced by treatment with hydrogen and catalytic palladium to provide amine 23. 10 Amine 23 is acylated with sulforyl chloride 7 to give the corresponding sulfonamide 24. Reduction of compound 24 with cobalt chloride and sodium borohydride provides the desired amine 25.

15

5

20



30


Alternatively, diamine 5 where X is -CH₂CH₂- and m is 1 is available from intermediate 23 by reduction of the nitrile group with, for example, cobalt chloride and sodium borohydride. This diamine may then be modified as illustrated in Scheme 3.

Intermediates II and III are coupled by heating them neat or as a solution in a polar solvent such as methanol, acetonitrile, tetrahydrofuran, dimethylsulfoxide or N-methyl pyrrolidinone for 1 to 24 hours at temperatures of 30 to 150° C to provide compounds I as shown in Scheme 8. The reaction is conveniently conducted in refluxing methanol. Alternatively, a salt of amine III, such as the

- 21 -

trifluoroacetate or hydrochloride salt, may be used. In these cases, a base such as sodium bicarbonate or diethylisopropylamine is added to the reaction mixture. The product is purified from unwanted side products by recrystallization, trituration, preparative thin layer chromatography, flash chromatography on silica gel as described by W. C. Still, <u>et. al.</u>, J. Org. Chem. <u>43</u>, 2923 (1978), medium pressure liquid chromatography, or HPLC. Compounds which are purified by HPLC may be isolated as the corresponding salt. Purification of intermediates is achieved in the same manner.





25

5

10

15

20

In some cases, the coupling product I from the reaction described in Scheme 8 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on, in particular, R¹ and R⁷. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.

An alternate method for the synthesis of compound I is illustrated in Scheme 9. Epoxide II is coupled to amine 5 as described above for coupling intermediates II and III (Scheme 8) to give aniline derivative 27. The secondary amine is selectively protected, for example, as a carbamate by treatment with dj-*tert*-butyldicarbonate to provide carbamate 29. Alternatively, nitro amine 26 is used in the coupling reaction to provide 28. Following protection as described above, the nitro group is reduced, for example, by catalytic hydrogenation, to provide intermediate 29. Treatment with a sulfonyl chloride in the presence of a base such as pyridine followed by removal of the protecting group with, in the case of a *tert*-butylcarbamate, acid such as trifluoroacetic acid or methanolic hydrogen chloride, provides the sulfonamide I.


15

10

5

20

25




10

In some cases, compound I from the reaction sequence illustrated in Scheme 9 may be further modified, for example, by the 30 removal of protecting groups or the manipulation of substituents on, in particular, R1 and R7, as described above. In addition, manipulation of substituents on any of the intermediates in the reaction sequence illustrated in Scheme 9 may occur. One such example is illustrated in Scheme 10. Compound 30, which is prepared as outlined in Scheme 9 from the corresponding epoxide, is subjected to reduction using tin(II)

- 24 -

chloride to provide compound 31. Other examples of substituents on compound I which may be reduced to the corresponding amine by methods commonly known to those skilled in the art include nitro groups, nitriles, and azides.

SCHEME 10



The compounds (I) of the present invention can also be prepared from amine intermediates such as those of formula III and haloketone intermediates such as those of formula 2, as shown in 25 Scheme 11. Amine III is alkylated with haloketone derivative 2, conveniently by treatment of a mixture of III and 2 with base such as potassium carbonate or triethylamine in a polar solvent such as acetonitrile, acetone or dimethylformamide. The resultant aminoketone 32 is reduced with, for example, sodium borohydride in methanol to

30


5

10

15

20

give the desired aminoalcohol I.



- 25 -

10

5

15

20

25

In some cases, the product I from the reaction described in Scheme 11 may be further modified, for example, by the removal of protecting groups or the manipulation of substituents on, in particular, R1 and R7. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.

ĭ

[H]

Compounds of the general Formula 1 may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.

Alternatively, any enantiomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials of known configuration.

5

10

15

20

25

30

- 26 -

The instant compounds can be isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like. In

addition, certain compounds containing an acidic function such as a carboxy or tetrazole, can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.

As previously indicated, the compounds of the present invention have valuable pharmacological properties.

The present invention also provides a compound of the general Formula I or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance.

In one aspect, the present invention provides a compound of the general Formula I or a pharmaceutically acceptable ester thereof: or a pharmaceutically acceptable salt thereof for use in the treatment of obesity in human or non-human animals.

The present invention further provides a compound of the general Formula I, or a pharmaceutically acceptable ester thereof; or pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycemia (diabetes) in human or non-human animals.

The disease diabetes mellitus is characterized by metabolic defects in production and utilization of glucose which result in the failure to maintain appropriate blood sugar levels. The result of these defects is elevated blood glucose or hyperglycemia. Research on the treatment of diabetes has centered on attempts to normalize fasting and postprandial blood glucose levels. Treatments have included parenteral administration of exogenous insulin, oral administration of drugs and dietary therapies.

Page 30 of 108

Two major forms of diabetes mellitus are now recognized. Type I diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type II diabetes, or insulin-independent diabetes, often occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type II diabetics are also obese.

5

10

15

20

2

In addition the compounds of the present invention lower triglyceride levels and cholesterol levels and raise high density lipoprotein levels and are therefore of use in combatting medical conditions wherein such lowering (and raising) is thought to be beneficial. Thus they may be used in the treatment of hypertriglyceridaemia, hypercholesterolaemia and conditions of low HDL (high density lipoprotein) levels in addition to the treatment of atherosclerotic disease such as of coronary, cerebrovascular and peripheral arteries, cardiovascular disease and related conditions.

Accordingly, in another aspect the present invention provides a method of lowering triglyceride and/or cholesterol levels and/or increasing high density lipoprotein levels which comprises administering, to an animal in need thereof, a therapeutically effective amount of a compound of the formula (I) or pharmaceutically acceptable salt thereof. In a further aspect the present invention provides a method of treating atherosclerosis which comprises administering, to an animal in need thereof; a therapeutically effective 25 amount of a compound of the formula (1) or pharmaceutically acceptable salt thereof. The compositions are formulated and administered in the same general manner as detailed below for treating diabetes and obesity. They may also contain other active ingredients known for use in the treatment of atherosclerosis and related conditions,

30 for example fibrates such as clofibrate, bezafibrate and gemfibrozil; inhibitors of cholesterol biosynthesis such as HMG-CoA reductase inhibitors for example lovastatin, sinvastatin and pravastatin; inhibitors of cholesterol absorption for example beta-sitosterol and (acyl CoA:cholesterol acyltransferase) inhibitors for example melinamide;

Page 31 of 108

- 27 -

anion exchange resins for example cholestyramine, colestipol or a dialkylaminoalkyl derivatives of a cross-linKed dextran; nicotinyl alcohol, nicotinic acid or a salt thereof; vitamin E; and thyromimetics.

- 28 -

The compounds of the instant invention also have the effect of reducing intestinal motility and thus find utility as aiding in the treatment of various gastrointestinal disorders such as irritable bowel syndrome. It has been proposed that the motility of non-sphincteric smooth muscle contraction is mediated by activity at \$3

adrenoreceptors. The availability of a \$3 specific agonist, with little activity at β_1 and β_2 receptors will assist in the pharmacologic control of intestinal motility without concurrent cardiovascular effects. The instant compounds are administered generally as described below with dosages similar to those used for the treatment of diabetes and obesity.

It has also been found unexpectedly that the compounds 15 which act as agonists at B3 adrenoreceptors may be useful in the treatment of gastrointestinal disorders, especially peptic ulcerations. esophagitis, gastritis and duodenitis, (including that induced by H. pylori), intestinal ulcerations (including inflammatory bowel disease, ulcerative colitis, Crohn's disease and proctitis) and gastrointestinal ulcerations.

In addition, β_3 receptors have been indicated to have an effect on the inhibition of the release of neuropeptides in certain sensory fibers in the lung. As sensory nerves may play an important role in the neurogenic inflammation of airways, including cough, the instant specific β_3 agonists may be useful in the treatment of neurogenetic inflammation, such as asthma, with minimal effects on the cardiopulmonary system.

β3 adrenoreceptors are also able to produce selective antidepressant effects by stimulating the B3 receptors in the brain and thus an additional contemplated utility of the compounds of this invention are as antidepressant agents.

The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be

10

5

20

30

enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incorporated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray.

5

10

15

4

30

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated.

When treating diabetes mellitus and/or hyperglycemia generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1.0 milligrams to about 1000 milligrams, preferably from about 1 milligrams to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

When treating obesity, in conjunction with diabetes and/or hyperglycemia, or alone, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from 1 milligram to about 1000 milligrams per kilogram of animal body weight, preferably given in divided doses two to six times a day, or in sustained release form. For most large mammals, the total

Page 33 of 108

- 29 -

daily dosage is from about 10 milligrams to about 10,000 milligrams, preferably from about 10 milligrams to about 500 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 70 milligrams to about 3500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

- 30 -

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and

5

15

10

20

25

.30



10

20

25

30




- 31 -

liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

The following examples are provided so that the invention might be more fully understood. They should not be construed as limiting the invention in any way.

EXAMPLE 1




15 (<u>R</u>)-<u>N</u>-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2-(tetrazolo[1,5-a]pyrid-6yl)ethylamine

A solution of 1.62 g (10 mmol) of (R)-2-(tetrazolo[1,5a]pyrid-6-yl)oxirane (See Fisher and Wyvratt, European Patent Application 0 318 092 A2 for the synthesis of this compound.) and 4.1 g (30 mmol) of 2-(4-aminophenyl)ethylamine in 30 mL of methanol was heated at reflux for 5h. The reaction mixture was concentrated and the residue chromatographed on silica gel (2% methanol/98% methylene chloride) to give 1.69 g (56%) of the title compound: ¹H NMR (400 MHz, CD3OD) δ 9.01 (d, 1H, J =1.3 Hz), 8.02 (d,1 H, J = 9.2 Hz), 7.82 (dd, 1H, J = 1.3, 9.2 Hz), 6.94 (d, 2H, J = 6.3 Hz), 6.63 (d, 2H, J = 6.3

Hz), 4.91 (m, 1H), 2.82 (m, 4H), 2.67 (t, 2 H, J = 7.1Hz).






(<u>R</u>)-<u>N</u>-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2-(tetrazolo[1,5-a]pyrid-6yl)ethylcarbamic acid 1,1-dimethylethyl ester

A solution of 1.69 g (56.7 mmol) of the amine from Example 1 and 1.23 g (56.7 mmol) of di-<u>tert</u>-butyl dicarbonate in 10 mL of tetrahydrofuran (THF) at 0° C was stirred for 2 h. The reaction mixture was concentrated and the residue chromatographed on silica gel (4% methanol/96% methylene chloride) to afford 2.2 g (97%) of the title compound: ¹H NMR (400 MHz, CD3OD) δ 8.96 (s, 1H), 8.05 (m, 2H), 7.85 (m, 2H), 6.93 (dd, 2H, J = 7.7, 8.3 Hz), 6.66 (d, 2H, J = 8.3 Hz), 4.99 (m, 1H), 3.49 (m, 4H), 2.70 (t, 2H, J = 6.5 Hz), 1.26 (s, 9H).

EXAMPLE 3



4-(Hexylaminocarbonylamino)benzenesulfonyl chloride

Hexylamine, 12.15 ml (9.2 mmol), was added dropwise to a solution of 10 ml (9.2 mmol) of phenyl isocyanate in THF (150 ml) at 0°C, and stirring was continued for 1 h. The solvent was removed *in* vacuo, and the resultant hexyl phenyl urea was used without further purification.

A 6-g (2.7 mmol) portion was added over 20 min to chlorosulfonic acid at 0°C, followed by heating at 60°C for 2h. After cooling, the mixture was added to ice/water (100ml) and the aqueous phase extracted with EtOAc (3x100 ml). The combined organic phase was washed with brine (50 ml), dried with MgSO4, concentrated, and

³⁰ purified by flash chromatography (silica gel, 75% hexane/ 25% ethyl acetate) to give 6 g (70%) of the title compound: ¹H NMR (CDCl3) δ 7.85 (d, 2H, J = 9.6 Hz), 7.54 (d, 2H, J = 9.6 Hz), 6.79 (br.s, 1H), 4.71(br. s, 1H), 3.23 (t, 2H, J = 8 Hz), 1.54-1.44 (m, 2H), 1.33-1.20 (m, 6H), 0.91-0.79 (m, 3H).

15

20

25

10

5

5

19203


1.42





- 33 -

EXAMPLE 4



10

15


20

5


 $(\underline{R})-\underline{N}-[4-[2-[\underline{N}-(1,1-dimethy]ethoxycarbonyl])-\underline{N}-[2-hydroxy-2-(tetra-zolo[1,5-a]pyrid-6-yl]]ethyl]amino]ethyl]phenyl]-4-(hexylaminocarbon-ylamino)benzenesulfonamide$

To a stirred solution of 0.200 g (0.502 mmol) of the Boccompound from Example 2 in 3 mL of methylene chloride was added 80 mg (1.00 mmol) of pyridine followed by 0.16 g (0.75 mmol) of the sulfonyl chloride from Example 3. After being stirred for 5h, the reaction mixture was concentrated and the residue chromatographed on silica gel (10% methanol/90% methylene chloride) to afford 0.303 g (88%) of the title compound: ¹H NMR (400 Hz, CD3OD) δ 8.95 (s, 1H), 8.0-8.08 (m, 1H), 7.75-7.87 (m, 1H), 7.40-7.62 (m, 4H), 7.00 (m, 4H), 4.95 (m, 2H), 3.47 (m, 2H), 3.15 (m, 2H), 2.75 (m, 2H), 1.52 (t, 2H, J = 6.0 Hz), 1.33 (m, 8H), 1.21 (s, 9H), 0.90 (t, 3H, J = 6.0 Hz).

EXAMPLE 5



30



A mixture of 0.302 g (0.44 mmol) of the tetrazine from Example 4, 0.20 g (0.88mol) of tin(II) chloride dihydrate and 0.3 ml of concentrated aqueous hydrochloric acid in 2 mL of methanol was heated at reflux for 5 h. The reaction mixture was concentrated and the residue purified by reverse-phase MPLC (C8, 47%methanol/53 0.1% trifluoroacetic acid buffer) to give 0.32 g (78%) of the title compound as its bistrifluoroacetate salt: ¹H NMR (400 MHz, CD3OD) δ 7.96 (dd, 1H, J = 2.0, 9.2 Hz), 7.86 (d, 1H, J = 2.0 Hz), 7.59 (d, 2H, J = 8.8 Hz), 7.43 (d, 2H, J = 8.8 Hz), 7.14 (d, 2H, J = 8.4 Hz), 7.07 (d, 2H, J = 8.4 Hz), 7.03 (d, 1H, J = 9.2 Hz), 4.92 (m, 1H), 3.23 (m, 2H), 3.15 (m, 2H), 2.93 (m, 2H, 4.0 Hz), 1.49 (t, 2H, J = 6.0Hz), 1.32 (m, 8H), 0.91 (t, 3H, J = 6.0 Hz); CI MS *m*/z 555(M+1).

15


20

10

5

Following the procedures outlined for Examples 1-5, the compounds listed in Table 1 were prepared.

TABLE 1



	Example	R	Selected ¹ H NMR (CD3OD) Data
	6	Ph, trifluoroacetate salt	7.74 (m,2H), 7.53 (m, 1H), 7.45 (m, 2H).
30	7	2-naphthyl, trifluoroacetate salt	7.93 (m, 4H), 7.75 (d, 1H, J = 1.7 Hz), 7.61 (m, 2H)
	8	3-quinolinyl, trifluoroacetate salt	9.00 (d, 1H, J = 2.3 Hz), 8.06 (m, 2H), 7.94 (m, 2H), 7.72 (t, 1H, J = 7.2 Hz)

25




- 35 -

19203

9	1,2-benzisoxazol-5-yl, trifluoroacetate salt	9.02 (s, 1H), 8.30 (d, 1H, J = 1.3 Hz), 7.90 (m, 1H), 7.77 (m, 1H)
10	4-iodophenyl, trifluoroacetate salt	7.83 (d, 2H, J = 8.6 Hz), 7.46 (d, 2H, J = 8.6 Hz)
11	4-[(N-hexyl,N-methyl- aminocarbonyl)amino]- phenyl, trifluoroacetate salt	7.62 (d, 2H, J = 4.6 Hz), 7.48 (d, 2H, J = 4.6Hz), 2.99 (s, 3H)
12	4-[(N,N-dimethyl- aminocarbonyl)amino]- phenyl, trifluoroacetate salt	3.0 (s, 6H)
13	trifluoroacetate salt	3.88-3.83 (m, 2H), 3.57-3.50 (m, 2H), 2.89-2.95 (m, 2H), 1.61-1.52 (m, 2H), 1.37-1.30 (m, 6H), and 0.93-0.88 (m,3H)

EXAMPLE 14



3-(2-Chloroacetyl)pyridine hydrochloride

To a solution of 12 g (11 mL, 100 mmol) of 3acetylpyridine in 100 mL of ethyl ether was added 100 mL of 1 M ethereal hydrogen chloride. The resultant precipitate was filtered and 15.0 g (95.2 mmol) was collected and placed in a 500-mL round bottom flask equipped with a magnetic stir bar. To this was added 95 mL of 1 M hydrogen chloride in acetic acid. After the mixture was stirred until all the solid had dissolved, 12.7 g (95.2 mmol) of <u>N</u>-chlorosuccinimide (NCS) was added in one portion. The solution turned yellow and the

25


30

- 36 -

19203

NCS gradually dissolved. After 4 h, a white precipitate had formed. The mixture was allowed to stir for 2.5 days. It was then filtered. The solid collected was washed with 10 mL of acetic acid and 200 mL of ethyl ether to give 15.2 g (83%) of the title compound as a white solid: 1H NMR (200 MHz, d₆-DMSO) δ 9.22 (t, 1H, J = 1 Hz), 8.29 (dd, 1H, J = 1.6, 5.1 Hz), 8.55 (td, 1H, J = 2, 8.1 Hz), 7.82 (ddd, 1H, J = 0.8, 5.1, 8.1 Hz), 5.27 (s, 2H).

EXAMPLE 15



15

10

5

(R)-a-Chloromethyl-3-pyridinemethanol

To a stirred solution of 3.67 g (11.5 mmol) of (-)-<u>B</u>-chlorodiisopinocampheylborane [(-)-DIP-Cl] in 11 mL of THF at -25 °C was added a slurry of 1.00 g (5.21 mmol) of the product from

20

Example 14 in 5 mL of THF via a cannula. Following the addition of 0.80 mL (5.79 mmol) of triethylamine, the reaction mixture was stirred at -25 °C for 4 days. To the mixture was added 10 mL of water which was then allowed to warm to room temperature. To the mixture was added 20 mL of ethyl acetate and the organic phase separated. The

²⁵ aqueous phase was neutralized with saturated NaHCO3 solution then extracted six times with ethyl acetate. The combined organic phase was concentrated in vacuo to afford a yellow oil. Flash chromatography (silica gel, 75 - 100% ethyl acetate-hexanes) afforded 561 mg (68%) of the title compound as a pale yellow oil: ¹H NMR (400 MHz, CD3OD) δ


³⁰ 8.58 (d, 1H, J = 1.8 Hz), 8.46 (dd, 1H, \hat{J} = 4.9, 1.5 Hz), 7.90 (d, 1H, J = 7.9 Hz), 7.44 (dd, 1H, J = 7.9, 4.9 Hz), 4.93 (m, 1H), 3.75 (m, 2H).





- 37 -

EXAMPLE 16



(R)-(Pyrid-3-yl)oxirane


To a solution of 557 mg (3.55 mmol) of the product from Example 15 in 16 mL of acetone was added 1.80 g of potassium carbononate. The mixture was heated at reflux for 20 h then cooled to room temperature. The mixture was filtered and the filtrate evaporated in vacuo. Flash chromatography (silica gel, 2% methanol-methylene chloride) afforded 262 mg (61%) of the title compound as a pale yellow oil: ¹H NMR (200 MHz, CDCl₃) δ 8.54 (m, 2H), 7.52 (m, 1H), 7.24

(m, 1H), 3.86 (dd, 1H, J = 4.0, 2.5 Hz), 3.17 (dd, 1H, J = 5.4, 4.0 Hz), 2.80 (dd, 1H, J = 5.4, 2.5 Hz).

EXAMPLE 17

20

5



25


30

(R)-N-[2-[4-(Aminophenyl)]ethyl]-2-hydroxy-2-(pyrid-3-yl)ethylamine To a stirred solution of 377 mg (2.44 mmol) of
4-aminophenethylamine in 10 mL of methanol was added a solution of 300 mg (2.48 mmol) of the product from Example 16 in 15 mL of methanol. The mixture was heated at reflux for 16 h then cooled to room temperature. The methanol was removed in vacuo and the residue chromatographed (silica gel, 6 - 8% methanol, 1% ammonia-methylene chloride) to afford 101 mg (16%) of the title compound together with 279 mg of a mixture that was rechromatographed (5% methanol, 1% ammonia-methylene chloride) to give a further 54 mg (9%) of the title

Page 41 of 108

compound as an off-white solid: ¹H NMR (500 MHz, CD3OD) δ 8.52 (d, 1H, J = 1.8 Hz), 8.43 (dd, 1H, J = 4.8, 1.4 Hz), 7.81 (m, 1H), 7.40 (m, 1H), 6.95 (d, 2H, J = 8.3 Hz), 6.67 (d, 2H, J = 8.3 Hz), 4.81 (m, 1H), 2.90-2.65 (m, 6H).

EXAMPLE 18



(<u>R</u>)-<u>N-[2-[4-(aminophenyl)]ethyl]-2-hydroxy-2-(pyrid-3-yl)ethylcarbamic acid 1.1-dimethylethyl ester</u>

A solution of 386 mg (1.77 mmol) of di-<u>tert</u>-butyl dicarbonate in 3.5 mL of THF was added, via a cannula, to a stirred slurry of 456 mg (1.77 mmol) of the product from Example 17 in 3.6 mL of THF cooled to 0 °C. The yellow solution was stirred at 0 °C for 3 h, then the THF was removed in vacuo. Flash chromatography (silica gel, 10% methanol, 1% ammonia-methylene chloride) afforded 549 mg (87%) of the title compound as an off white solid: ¹H NMR (500 MHz, CD₃OD, mixture of rotomers) δ 8.45 (m, 2H), 7.83 (d, 0.6H, J = 7.4 Hz), 7.78 (d, 0.4H, J = 6.9 Hz), 7.41 (m, 1H), 6.94 (d, 0.8H, J = 8.0 Hz), 6.89 (d, 1.2H, J = 7.8 Hz), 6.66 (d, 2H, J = 7.3 Hz), 4.89 (m, 1H), 3.42-3.21 (m, 4H), 2.67 (m, 2H), 1.39 (s, 5.4H), 1.36 (s, 3.6H).

30

25

19203

15

20


10





- 39 -

EXAMPLE 19



10

5

(<u>R</u>)-<u>N</u>-[4-[2-[[2-Hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-(hexylaminocarbonylamino)benzenesulfonamide

- To a solution of 302 mg (0.845 mmol) of the product from
 Example 18 and 137 μL (1.69 mmol) of pyridine in 10 mL of
 methylene chloride was added 296 mg (0.928 mmol) of
 4-(hexylaminocarbonylamino)benzenesulfonyl chloride from Example
 3. The reaction was stirred for 12 h then the solvent removed in vacuo.
 Flash chromatography (silica gel, 6% methanol, 0.5% ammonia-
- 20 methylene chloride) afforded 468 mg (87%) of the BOC-protected title compound.

A solution of 468 mg (0.731 mmol) of BOC-protected title compound in 5 mL of methylene chloride and 5 mL of trifluoroacetic acid was stirred for 30 min then the volatile components removed in vacuo. The residue was azeotroped twice with 10% methanol/toluene, twice with methanol, then dried in vacuo to give 521 mg (93%) of the title compound as its trifluroracetate salt: ¹H NMR (400 MHz, CD3OD) δ 8.88 (s, 1H), 8.79 (d, 1H, J = 5.5 Hz), 8.53 (d, 1H, J = 8.2 Hz), 7.99 (m, 1H), 7.59 (dd, 2H, J = 6.9, 1.9 Hz), 7.43 (dd, 2H, J = 6.9, 1.9 Hz), 7.15 (dd, 2H, J = 8.6, 2.1 Hz), 7.08 (dd, 2H, J = 8.6, 2.1 Hz); 5.23 (m,

1H), 3.40-3.10 (m, 6H), 2.94 (m, 2H), 1.49 (m, 2H), 1.32 (m, 6H), 0.90 (m, 2H).

Following the procedures outlined for Examples 14-19, the compounds listed in Table 2 were prepared.






- 40 -

TABLE 2






10	Example	R	Selected 1H NMR (CD3OD) Data
	20	4-isopropylphenyl	7.64 (d, 2H, J = 8.0 Hz), 7.33 (d, 2H, J = 8.0 Hz), 4.80 (m, 1H), 2.95- 2.70 (m, 7H), 1.22 (d, 6H, J = 6.7 Hz)
15	21	4-iodophenyl, trifluoroacetate salt	7.84 (d, 2H, J = 8.6 Hz), 7.47 (d, 2H, J = 8.6 Hz), 5.19 (dd, 1H, J = 10.1, 3.0 Hz), 3.40-3.20 (m, 4H), 2.96 (m, 2H)
	22	2-naphthyl	8.28 (s, 1H), 7.94 (m, 3H), 7.72 (dd, 1H, J = 8.7, 1.9 Hz), 7.60 (m, 2H)
20	23	3-quinolinyl, trifluoroacetate salt	9.01 (d, 1H, J = 2.3 Hz), 8.76 (d, 1H, 1.8 Hz), 8.08 (d, 1H, J = 8.7 Hz), 8.04 (d, 1H, J = 8.0 Hz), 7.93 (m, 1H), 7.73 (m, 1H)
25	24	4-[(N-hexyl,N-methyl- aminocarbonyl)amino]- phenyl, trifluoroacetate salt	5.12 (d, 1H, J = 8.7 Hz), 3.40-3.10 (m, 6H), 2.99 (s, 3H), 2.95 (m, 2H), 1.56 (m, 2H), 1.31 (m, 6H), 0.88 (m, 3H)
30	25	trifluoroacetate salt	5.15 (m, 1H), 3.85 (m, 2H), 3.53 (m, 2H), 3.40-3.15 (m, 6H), 2.94 (m, 2H), 1.55 (m, 2H), 1.32 (m,- 6H), 0.89 (m, 3H).



Starting with commercially available (<u>R</u>)-styrene epoxide and following the procedures outlined for Examples 17-19, the compounds listed in Table 3 were prepared.

- 41 -



10

5

	Example	R	Selected 1H NMR (CD3OD) Data
15	26	4-iodophenyl, trifluoroacetate salt	7.84 (d, 2H, J = 8.6 Hz), 7.45 (d, 2H, J = 8.5 Hz)
	27	2-naphthyl, trifluoroacetate salt	8.31 (s, 1H), 7.96-7.90 (m, 3H), 7.74 (dd, 1H, J = 1.8, 8.7 Hz), 7.63 (t, 1H), 7.58 (t, 1H)
20	28	3-quinolinyl, trifluoroacetate salt	9.01 (d, 1H, J = 2.2 Hz), 8.75 (d, 1H, J = 2.1 Hz), 8.07 (d, 1H, J = 8.4 Hz), 8.03 (d, 1H, J = 8.3 Hz), 7.92 (t, 1H, J = 7.0 Hz), 7.72 (t, 1H, J = 7.1 Hz)

25






- 42 -

WHAT IS CLAIMED IS:

1. A compound having the formula I:



10

5

	where	2
	n is	0 to 5;
15	m is	0 or 1;
10	r is	0 to 3;
	A is	-phenyl,
		to 4 het

yl, a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, a benzene ring fused to a C3-C8 cycloalkyl ring, a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, or a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; hydroxy, oxo, halogen, cyano, NR8R8, SR8 trifluoromethyl, C1-C6 alkyl, C1-C6 alkoxy, SO2R9, OCOR9, NR8COR9, COR9, NR8SO2R9, NR8CO2R8, or C1-C6 alkyl substituted by hydroxy, halogen, cyano, NR8R8, SR8, trifluoromethyl, C1-C6 alkoxy, C3-C8 cycloalkyl, phenyl, NR8COR9, COR9, SO2R9, OCOR9, NR⁸SO₂R⁹ or NR⁸CO₂R⁸;

A H

R1 is

20

	R ² and R ³	are independently hydrogen, C1-C6 alkyl or C1-C6 alkyl with 1 to 3 substituents selected from hydroxy, C1-C6
5	X is R4 and R5	alkoxy, and halogen; -CH2-, -CH2-CH2-, -CH=CH- or -CH2O-; are independently hydrogen, C1-C6 alkyl, halogen, NHR ⁸ , OR ⁸ , SO2R ⁹ or NHSO2R ⁹ ;
	R6 is R7 is	hydrogen or C ₁ -C ₆ alkyl; Z-(R ^{1a})n;
10	R ¹ is	R ¹ , C3-C8 cycloalkyl, phenyl, or 5 or 6-membered heterocycle with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to three groups independently selected from oxo, R ⁸ and NR ⁸ R ⁸ ;
15	Z is	phenyl, naphthyl, a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen, a benzene ring fused to a C3-C8 cycloalkyl ring, a benzene ring fused to a 5 or 6-membered
20		heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, or a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen fused to a 5 or 6- membered heterocyclic ring with from 1 to 3 heteroatoms
25	R ⁸ is	selected from oxygen, sulfur and nitrogen; hydrogen, C1-C10 alkyl, C3-C8 cycloalkyl, Z optionally having 1 to 3 substituents selected from halogen, C1-C6 alkyl and C1-C6 alkoxy, or C1-C10 alkyl having 1 to 3 substituents selected from hydroxy, halogen, C02H, C02- C1-C6 alkyl, S02-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6
30	D Û :	alkoxy, and Z optionally substituted by from 1 to 3 of halogen, C1-C6 alkyl or C1-C6 alkoxy; R8 or NR8R8; or
	R ⁹ is	
	a pharma	centically acceptable salt thereof

2. A compound of Claim 1 where 19203

- 43 -

 $\Lambda_{\rm c}$

 \mathbf{a}^{i}

- 1

- 44 -

19203

0 to 3; n is m is 1; 0 to 2; r is -phenyl, or a 5- or 6-membered heterocyclic ring with from A is 1 to 4 nitrogen atoms; X is -CH2-: hydroxy, halogen, cyano, trifluoromethyl, NR8R8, R¹ is NR⁸SO₂R⁹, NR⁸COR⁹, NR⁸CO₂R⁸, C₁-C₆ alkyl optionally substituted by hydroxy; R², R³ are independently hydrogen or methyl; R⁴, R⁵ and R⁶ are each hydrogen; and


Z and R^{1a} are as defined in Claim 1.

15

10

3. A compound of Claim 1 having the formula Ia:

la



20

wherein	
n is	0 to 3;
m is	1
R ¹ is	halogen or NR ⁸ R ⁸ ;
Rla is	halogen, C1-C6 alkyl, NR ⁸ R ⁸ , NR ⁸ COR ⁹ , NR ⁸ CO ₂ R ⁸ ,
	OCOR ⁹ , or 5 or 6-membered heterocycle with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen,
	optionally substituted with up to three groups independently selected from oxo, R ⁸ and NR ⁸ R ⁸ ;
Z is	phenyl, naphthyl or benzene ring fused to a 5 or 6-
	membered heterocyclic ring with from 1 to 3 heteroatoms
	selected from oxygen, sulfur and nitrogen;
X is	-CH2-; and
	n is m is R ¹ is R ¹ a is Z is



10

15

20

25

30



R², R³ are independently hydrogen or methyl.

4. A compound of Claim 3 wherein R² and R³ are each hydrogen.

- 45 -

A\compound of Claim 1 having the formula Ib: 5. $H R^2$ NH-SO₂-Z-(R^{1a})_n HCH2N-C-(X)m 'nэ в wherein n is 0 to 3; m is hydroxy, NR8R8 or halogen? R¹ is halogen, C1-C6 alkyl, NR 8R8, NR8COR9, NR8CO2R8, R^{la} is OCOR9, or 5 or 6-membered heterocycle with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with up to three groups independently selected from oxo, R8 and NR8R8; phenyl, naphthyl or benzene ring fused to a 5 or 6-Zis membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen; -CH2-; and X is R^2 and R^3 are independently hydrogen or methyl. A compound of Claim 5 wherein R² and R³ are each 6. hydrogen. 7 A compound of Claim 1 selected from the group consisting of:



A



<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-y])ethyl]amino]ethyl]phenyl]-</u> 4-(hexylaminocarbonylamino)benzenesulfonamide;

N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-iodobenzenesulfonamide;

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-</u> benzenesulfonamide;

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl])ethyl]amino[ethyl]phenyl]-</u> 2-naphthalenesulfonamide;

<u>N</u>-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl] 3-quinolinesulfonamide;

N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-5-benzisoxazolesulfonamide;

<u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl]ethyl]amino]ethyl]phenyl]-</u> 4-{(hexylmethylaminocarbonyl)amino]benzenesulfonamide;

15 <u>N-[4-[2-][2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-</u> 4-[(dimethylaminocarbonyl)amino]benzenesulfonamide; <u>N-[4-[2-[[2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-</u> 4.(2-hydroxy-2-(4-aminopyridin-3-yl)ethyl]amino]ethyl]phenyl]-

4-(3-hexyl-2-imidazolidon-1-yl)benzenesulfonamide;

<u>N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-</u> (hexylaminocarbonylamino)benzenesulfonamide; <u>N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-</u> isopropylbenzenesulfonamide;

N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-2naphthalenesulfonamide;

25 <u>N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-3-</u> quinolinesulfonamide;

<u>N-</u>[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[(hexylmethylaminocarbonyl)amino]benzenesulfonamide;

<u>N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-(3-hexyl-2-imidazolidon-1-yl)benzenesulfonamide;</u>

N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4iodobenzenesulfonamide;






- 47 -

<u>N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-2-</u> naphthalenesulfonamide, and <u>N-[4-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]-3-</u> quinolinesulfonamide.

. 8, A compound of Claim 1 with the structural formula



15

25

30

10

5

Ic:

4

where n, m, r, A, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and X are as defined in Claim 1.

A method for the treatment of diabetes which comprises administering to a diabetic patient an effective amount of a compound of Claim 1.

10. A method for the treatment of obesity which comprises administering to an obese patient an effective amount of a compound of Claim 1.

N. A method for lowering triglyceride levels and cholesterol levels of raising high density lipoprotein levels which comprises administering to a patient needing lower triglyceride and cholesterol levels or higher high density lipoprotein levels an effective amount of a compound of Claim 1.

⁷⁶ 12. A method for decreasing gut motility which comprises administering to a patient in need of decreased gut motility, an effective amount of a compound of Claim 1.



1-2-

- 48 -

3. A method for reducing neurogenic inflammation of airways which comprises administering to a patient in need of reduced neurogenic inflammation, an effective amount of a compound of Claim 1.

14. A method for reducing depression which comprises administering to a depressed patient an effective amount of a compound of Claim 1.

13 A method for treating gastrointestinal disorders which comprises administering to a patient with gastrointestinal disorders an effective amount of a compound of Claim 1.

14 16. A composition for the treatment of diabetes or obesity or for lowering triglyceride or cholesterol levels or increasing high density lipoprotein levels or for decreasing gut motility or for reducing neurogenic inflammation or for treating depression or for treating gastrointestinal disorders which comprises an inert carrier and an effective amount of a compound of Claim-1.

25

20

5

10

15



- 49 -

19203

TITLE OF THE INVENTION

SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

ABSTRACT OF THE INVENTION

Substituted sulfonamides are selective β_3 adrenergic receptor agonists with very little β_1 and β_2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

20

5

10

15

25



C

tł

t

to

C

R



08/233,166

ATENT Case No. 19203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Declaration and power of attorney

Commissioner of Patents and Trademarks Washington, D.C. 20231

As a below-named inventor, I hereby declare that I believe I am the:

original, first and sole inventor; or

an original, first and joint inventor along with the other inventors listed below, of the subject matter which is

dained and for which a patent is sought on the invention entitled

SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA 3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

the specification of which 🛛

is attached hereto;

 was filed on __________as Application

 Serial No. ________and was amended

 through __________(if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including

the claims, as amended as indicated above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

Foreign Priority

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s)

for patent or inventor's certificate listed below and have also identified below any foreign application for patent or

inventor's certificate for the same invention having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Country	Number	Date Filed	Attorney Docket	Yes	No
		<u> </u>	1		
Country	Number	Date Filed	Attorney Docket	Yes	No

Priority Claimed

SECLARATION AND POWER OF ATTORNEY





Prior United States Filing

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

Appin. Ser. No.	Filing Date	Status	Attorney Dacket
Appin, Ser. No.	Filing Date	Status	Attorney Docket
Appin, Ser. No.	Filing Date	Status	Attorney Docket
Appin. Ser. No.	Filing Date	Status	Attorney Docket
Appin, Ser, No.	Filing Date	Status	Attorney Docket
Appin, Ser. No.	Filing Date	Status	Attorney Docket
Appin, Ser, No.	Filing Date	Status	Attorney Docket
Appin, Ser. No.	Fillng Date	Status	Attorney Docket

)	And I hereby appoint	
TOLLI	E M. YANG	

DAVID L. ROSE

Reg. No. 32,718

Reg. No. _26.332

Reg. No.

respectively and individually, as my attorneys or agents with full power of substitution and revocation, to prosecute this

application and to transact all business in the Patent and Trademark Office connected therewith. Please address all

communications to:

Mollie M. Yang Patent Department Merck & Co., Inc. P.O. Box 2000 Rahway, NJ 07065-0907

Telephone No. (908) 594- 6343

DECLARATION AND POWER OF ATTORNEY

inn

PATENT Case NO. 19203

I hereby declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

UDO

Full name of sole or joint inventor	Michael H. Fisher
Inventor's Signature	michael HFSB
Date	April 26, 1994
Residence	Bingoes, New Jersey 08551 NJ
Citizenship	United States
Post Office Address (if different from above)	P.O. Box 2000 Rahway, New Jersey 07065-0907

Full name of joint inventor	Elizabeth M. Naylor
Inventor's Signature	Eugabern M. Naybr
Date	April 25 1994
Residence	Scotch Plains, New Jersey 07076 Nゴ
Citizenship	United Kingdom
Post Office Address (if different from above)	P.O. Box 2000 Rahway, New Jersey 07065-090

Full name of joint inventor	Dong Ok
Inventor's Signature	Dong OK
Date	April 26, 1994
Residence	Edison. New Jersey 08820 NJ
Citizenship	United States
Post Office Address (if different from above)	P.O. Box 2000 Rahway, New Jersey 07065-0907

Full name of joint inventor	Ann E. Weber					
Inventor's Signature	ann E Weber					
Date	april 25, 1994					
Residence	Scotch Plains, New Jersey 07076 NJ					
Citizenship	United States					
Post Office Address (if different from above)	P.O. Box 2000 Rahway, New Jersey 07065-0907					

N





UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address : COMMISSIONER OF PATENTS AND TRADEMARKS

SERIAL NUMBER	FILING OATE	FIRST NAMED INVENTO	R	ATTORNEY DOCKET NO.
08/293.466	04726794	FISHER	14	19209
	1		LOBTHIN	幕を開からた フ
-		12#270805		
MOLLIE M. Y PATENT DEPT			L	
MERCK & CO.			ART UNIT	PAPER NUMBER
P.O. BOX 20	00		1203	2
RAHWAY, NJ	07065-0907		DATE MAILED:	08/05/94
s a communication from (b) WESTIONER OF PATENTS	e oxafaileer in charge of you \$ AND 'S HADEMARKS	r alxí Calon.		007 007 9 4
s application has been	examined [])	Responsive to communication filed on	L	This action is made final.
ened statutory period t	or response to this activ	on is set to expire three	ionih(s), da	ys from the date of this letter.
to respond within the p	eriod for response will	cause the application to become aben		Control and and a stranger and and a second
THE FOLLOWING		PART OF THIS ACTION:		C. State in the
1			an kan waa amaa	202
	ee Cited by Exeminer, P by Applicant, PTO-144		e re Palent Drawing, PTO e of Informal Patent App)	
	v to Effect Drawing Cha		or murman Patera App	calloll, Form Fr Q= Idz.
SUMMARY OF AC	TION			
. 1		2		
Claims	19			are panding in the application
Of the above	, claims 5 And	6		
Of the show	, claims	C/		withdrawn from consideration.
			- · ·	
				. have been cancelled.
🗆 Claims			- , arə	. have been cancelled.
_	4.07		8r8	
🗆 Claims	4 And 7.	- 16	6'18 	. have been cancelled.
Claims Claims Claims Claims	A And 7.	- 16		. have been cancelled. _ are allowed. _ are rejected.
Claims Claims Claims Claims Claime	A And 7.	- 16	6'18 	. have been cancelled. _ are allowed. _ are rejected.
Claims Claims Claims Claims	4 And 7.	- 16		. have been cancelled. _ are allowed. _ are rejected.
		- 16	_ are subject to restrictly	. have been cancelled. _ are allowed. _ are rejected. _ are objected to. on or election requirement.
Claims Claims Claims Claims Claims This application ba	s been filed with inform:	- 16 al drawings under 37 C:F.R. 1.85 which	_ are subject to restrictly	. have been cancelled. _ are allowed. _ are rejected. _ are objected to. on or election requirement.
Claims Claims Claims Claims Claims This application ba		- 16 al drawings under 37 C:F.R. 1.85 which	_ are subject to restrictly	. have been cancelled. _ are allowed. _ are rejected. _ are objected to. on or election requirement.
Claims Claims Claims Claims Claims This application tha Formal drawings ar	s-been filed with Inform: required in response	- 16 al drawings under 37 C:F.R. 1.85 which	– are subject to restrictly h are acceptable for exer	. have been cancelled. _ are allowed. _ are rejected. _ are objected to. on or election requirement. nination purposes.
Claims Claims Claims Claims Claims This application that Formal drawings ar The corrected or si	s been filed with Inform: e required in response ibstilute drewings have	- 16 al drawings under 37 C:F.P. 1.85 while to This Office action.	_ are subject to restrictly h are acceptable for exer Under 37 C.F	. have been cancelled. _ are allowed. _ are rejected. _ are objected to. on or election requirement. nination purposes.
	s been filed with Inform: e required in response ibstitute drewings have a. 🔲 not acceptable (a	- 16 al drawings under 37 C.F.P. 1.85 which to This Office action. Deen received on ee explanation or Notice re Patent Dra	_ are subject to restrictly h are acceptable for exer Under 37 C.F awing, PTO-948).	. have been cancelled. are ellowed. are rejected. are objected to. on or election requirement. ninetion purposes.
	s been filed with Inform: e required in response ibstitute drewings have a. 🔲 not acceptable (a	- 16 al drawings under 37 C.F.A. 1.85 which to This Office action. Deen received on es explanation or Notice re Patent Dra et(s) of drawings, filed on	_ are subject to restrictly h are acceptable for exer Under 37 C.F awing, PTO-948).	. have been cancelled. are ellowed. are rejected. are objected to. on or election requirement. ninetion purposes.
Claims Claims Claims Claims Claims Claims Claims Claims This application tha Formal drawings ar The corrected or si are are Ecceptabl The proposed addir examiner dase	s been filed with inform: e required in response ibstitute drawings have a not ecceptable (a tional or subalitute abec pproved by the examine	- 16 al drawings under 37 C.F.P. 1.85 which to This Office action. Deen received on ee explanation or Notice re Patent Dra ef(s) of drawings, filed on er (see explanation).	_ are subject to restrictly h are acceptable for exer Under 37 C.F awing, PTO-948). has (heve) been 1	 have been cancelled. are ellowed. are rejected. are objected to. or or election requirement. ninetion purposes. R. 1.64 these drewings approved by the
Claims Claims Claims Claims Claims Claims Claims Claims This application tha Formal drawings ar The corrected or si are are Ecceptabl The proposed addir examiner dase	s been filed with inform: e required in response ibstitute drawings have a not ecceptable (a tional or subalitute abec pproved by the examine	- 16 al drawings under 37 C.F.A. 1.85 which to This Office action. Deen received on es explanation or Notice re Patent Dra et(s) of drawings, filed on	_ are subject to restrictly h are acceptable for exer Under 37 C.F awing, PTO-948). has (heve) been 1	 have been cancelled. are ellowed. are rejected. are objected to. or or election requirement. ninetion purposes. R. 1.64 these drewings approved by the
Claims Claims Claims Claims Claims Claims Claims Claims This application ha Formal drawings ar The corrected or su areacceptabl The proposed addir examinerdise The proposed draw	s-been filed with informs to required in response abstitute drawings have s not acceptable (s tional or substitute shee pproved by the exemin-	al drawings under 37 C.F.A. 1.85 which to this Office action. been received on es explanation or Notice re Patant Dra et(s) of drawings, filed on er (see explanation).	_ are subject to restrictly h are acceptable for exer Under 37 C.F awing, PTO-948). has (heve) been approved disapprov	 have been cancelled. are allowed. are rejected. are objected to. on or election requirement. nination purposes. R. 1.64 these drewings approved by the ved (see explanation).
Claims Claims Claims Claims Claims Claims Claims Claims This application ha Formal drawings ar The corrected or si areacceptabl The proposed addir examinardase The proposed draw Acknowledgment is	s been filed with inform: e required in response ibstitute drewings have a not acceptable (s tional or subalitute shee pproved by the examine ing correction, filed on a made of the stalm for p	- 16 al drawings under 37 C.F.A. 1.85 which to this Office action. Deen received on ee explanation or Notice re Patent Dra ef(s) of drawings, filed on er (see explanation). , has been priority under U.S.C. 119. The certified	_ are subject to restrictly h are acceptable for exar Under 37 C.F has (here) been f approved disapprov copy has been rece	 have been cancelled. are allowed. are rejected. are objected to. on or election requirement. nination purposes. R. 1.84 these drawings approved by the ved (see explanation). ived D not been received
Claims Claims Claims Claims Claims Claims Claims Claims This application ha Formal drawings ar The corrected or si areacceptabl The proposed addir examinardase The proposed draw Acknowledgment is	s been filed with inform: e required in response ibstitute drewings have a not acceptable (s tional or subalitute shee pproved by the examine ing correction, filed on a made of the stalm for p	al drawings under 37 C.F.A. 1.85 which to this Office action. been received on es explanation or Notice re Patant Dra et(s) of drawings, filed on er (see explanation).	_ are subject to restrictly h are acceptable for exar Under 37 C.F has (here) been f approved disapprov copy has been rece	 have been cancelled. are allowed. are rejected. are objected to. on or election requirement. nination purposes. R. 1.84 these drawings approved by the ved (see explanation). ived D not been received
Claims Claims Claims Claims Claims Claims Claims Claims Claims application ha This application ha This application ha The proposed addir examinar diss The proposed draw Acknowledgment is Bince this application	s been filed with informs to required in response abstitute drewings have s not acceptable (s tional or substitute abec poroved by the examine ing correction, filed on a made of the claim for p rent application, serial o on appears to be in con	- 16	_ are subject to restrictly h are acceptable for exer Under 37 C.F has (here) been f approved disapprov copy has been rece f on melters, prosecution as t	 have been cancelled. are allowed. are rejected. are objected to. on or election requirement. nination purposes. R. 1.84 these drewings approved by the ved (see explanation). not been received
Claims Claims Claims Claims Claims Claims Claims Claims application ha This application ha This application ha The proposed addi examinar dase The proposed draw Acknowledgment is Bince this application	s been filed with informs to required in response abstitute drewings have s not acceptable (s tional or substitute abec poroved by the examine ing correction, filed on a made of the claim for p rent application, serial o on appears to be in con	- 16 al drawings under 37 C.F.R. 1.85 which to this Office action. been received on es explanation or Notice re Patant Dra et(s) of drawings, filed on er (see explanation). , has been priority under U.S.C. 119. The certified no; filed	_ are subject to restrictly h are acceptable for exer Under 37 C.F has (here) been f approved disapprov copy has been rece f on melters, prosecution as t	 have been cancelled. are allowed. are rejected. are objected to. or of election requirement. nination purposes. R. 1.84 these drewings approved by the ved (see explanation). ilved not been received
Claims Claims Claims Claims Claims Claims Claims Claims application ha This application ha This application ha The proposed addi examinar dase The proposed draw Acknowledgment is Bince this application	s been filed with informs to required in response abstitute drewings have s not acceptable (s tional or substitute abec poroved by the examine ing correction, filed on a made of the claim for p rent application, serial o on appears to be in con	- 16	_ are subject to restrictly h are acceptable for exer Under 37 C.F has (here) been f approved disapprov copy has been rece f on melters, prosecution as t	 have been cancelled. are allowed. are rejected. are objected to. on or election requirement. nination purposes. R. 1.84 these drewings approved by the ved (see explanation). ilved not been received

EXAMINER'S ACTION

Serial Number: 08/233,166

Art Unit: 1203

 This application contains claims directed to the following patentably distinct species of the claimed invention: A and R⁷.

The radicals within the definition of A and R⁷ are diverse in scope. A prior art reference which anticipates one member of A or R⁷ such as phenyl under 35 USC 102 would not render obvious another member such as pyridinyl under 35 USC 103. Accordingly, the radicals are independent and patentably distinct.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claim 1 is generic.

Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

-2-

Serial Number: 08/233,166 Art Unit: 1203

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

-3-

Serial Number: 08/233,166 Art Unit: 1203

2. During a telephone conversation with Mollie Yang on July 20, 1994 a provisional election was made with traverse to prosecute the invention of Example 25, claims 1-4 and 7-16. Affirmation of this election must be made by applicant in responding to this Office action. Claims 5 and 6 are withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention.

3. Applicant is reminded that upon the cancellation of claims to a nonelected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

4. Claims 1-4 and 7-16 are Markush claims which are generic to the elected invention. These Markush claims lack unity of invention for the reasons outlined above. Accordingly, the Markush type claim will be examined fully with respect to the elected species and further to the extent

-4-

Serial Number: 08/233,166

Art Unit: 1203

necessary to determine patentability. See MPEP 803.02.

5. Claims 1-4 and 7-16 are rejected on the grounds that the claims are drawn to an improper Markush group. <u>In re Harnish</u>, 206 USPQ 300, states that a unity of invention exists where compounds included within a Markush group(1) share a common utility and (2) share a substantial structural feature disclosed as being essential to that utility. In the instant case, the claimed subject matter does not share a substantial structural feature disclosed as being essential to that utility.

The requirement for a proper Markush claim is that it include only substances that in their physical, chemical and physiological characteristics are functionally equivalent. The members of the instant Markush groups possess widely different, physical and chemical properties. The compounds are not considered functionally equivalent and are so diverse that they demonstrate dissimilar and unrelated properties. The mere fact that there is structural similarity in pharmaceutical agents is not in itself reason to render all the embodiments functionally equivalent.

The improper Markush groups are A and R⁷.


-5-

Serial Number: 08/233,166

Art Unit: 1203

6. The examined subject matter is as follows:

A compound having the formula 1:



where A is pyridinyl;

 \mathbb{R}^7 is Z-(\mathbb{R}^{1a})n;

R^{1a} is R¹, C₃-C₈ cycloalkyl, phenyl;

Z is phenyl, naphthyl;

The radicals not recited above are as defined in claim 1.

Amending the claims to the examined subject matter would overcome the improper Markush rejection.

-6-

Scrial Number: 08/233,166

Art Unit: 1203

7. The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to adequately teach how the make the claimed invention.

The phrases "A or Z is a 5 or 6- membered heterocyclic ring with form 1 to 4 heteroatoms..sulfur and nitrogen fused to a 5 or 6-membered heterocyclic ring" and "R^{1a} is 5 or 6-membered heterocycle with form 1 to 3 heteroatoms...groups independently selected form oxo" appear at claim 1. A hypothetical compound can be embraced by the claim 1 definition, for instance, if A is pyridinyl, Z is benzene fused to a pyridinyl, R^{1a} is pyridinyl and n is 5. The specification does not adequately teach how to prepare such a bulky compound. Undue experimentation would be involved to prepare such a compound. Thus the Examiner concludes that the specification fails to teach how to prepare the claimed compounds.

-7-

Serial Number: 08/233,166

Art Unit: 1203

8. Claims 1- 4 and 7-16 are rejected under 35 U.S.C. § 112, first paragraph,

12 1 2

for the reasons set forth in the objection to the specification.

9. The prior art references are cited to show the state of the art. The

references do not anticipate nor render obvious the examined subject matter.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is (703) 308-4699.

A facsimile center has been established in Group 1200, room 3C10. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machine is (703) 308-4556 or 305-3592.

DAVISitcj July 27, 1994

Supervisory Patent Examine 1 Group120

-8-

		and the second sec	and the second se
TO SEPARATE, H.	AND BOTTOM EDGES.	SNAP-APART	AND DISCARD CARBON

(REV. 2-92) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						О ТЛАДЕМАВ		253,166			ATTA PA NU	CHME TO NPER MBEP		2			
	N	DTI	CE	OF	REF	ER	ENC	ES CITED		Fist	her et a	aL.					
T	T				_	_		1	U.S. PAT	ENT DOCL	MENTS	1	Г сі	JR.	less	NGOA	TF IF
Ļ.	L	D		IN CP	AT N	io.	5	DATE		NAME		CL 455		ASS		ROPH	
A	3	4	5	2	0	3	2	6-4-69	Sam			514	50	7			
8	4	3	9	6	6	2	7	8.2.83	Alasu	iorth	et el.	424	300	1	1		
c	4	4	7	8	8	4	9	10-23-84	Airsin	orth	et al.	424	28	5			
D	4	ġ	9	9	3	7	7	\$2-91		kett of		514	50	7			
E	5	D	とき	7	6	1	a	5-21.91		et al		514	653		T		
F								-	<u></u>					-		_	
G		-	-		-								-		1		
н	\vdash	-	-				-					-					
-	\vdash	_	-		\vdash	-			-				-				
Ľ	\vdash														\vdash		
1			_		_		_			_	2						
K									1								
	_								FOREIGNP	ATENT DO	CUMENTS						
		D	NCU	MEN	17 14	0.		DATE	col	VRTAI	NAME		ASS	CLAS		SHTS.	
L																	1
м										729							
N										- W							
0	1			-						• •							
P			- 1														
0			-						-					_	-		-
-		_	-	-		IER	R		 (Includio)	Author	Title, Date, P	ertinent Pa	ans E	ter 1	l	•	<u> </u>
Г	Γ-		-					- CHENGES	(menorie)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			3-3, -		-		
R	\vdash	-		-	_	-	-										
-	-	-	-	_	-		-										
s		_	-		_	-				_					_		
		_	_		_							_					_
1	L			_						1							
Ľ			_		_						_						
									_					_			
ľ		-								and the second							
	NER			à				DAT	e al								
1	18 1	At	1	2				122	1.64								

				WALL ROOM		PATENT Sheet 1	af 1
ORM PTO-144	9 U.S. DEPA PATENT A	RTMENT OF CO	MMERCE.	ATTY. DOCKET NO.	SERIA	-	of _1
2 10 C C C C C C C C C C C C C C C C C C	MATION DISCLOSU ae several sheets If r		ENT	APPLICANT(S) MICHAEL H. FISHER, E			
				FILING DATE Apr 26, 1994	GROU	PART UNIT	A.
			U.S. PA	TENT DOCUMENTS		(c)	3
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	APPROPRIATE
	3,816,516	6/11/74	D.A. CO	DX, ET AL	546	JUL	1.2
mo.	4,000,193	12/28/76	L.H.C.	LUNTS, ET AL	546	344	0
i)	4,396,627	- 8/2/83 -	A.T. AI	NSWORTH, ET AL			
	4,478,849	10/23/84	A.T. AI	NSWORTH, ET AL			
	4,999,377	3/12/91		CAULKETT, ET AL			
- <u> </u>	5,017,619	-5/21/91	L. ALIG	, ET AL			****
Spr. O.	5,153,210	10/6/92	A.T. AI	NSWORTH, ET AL	546	544	
V						· ·	
			-				
			-		-		
		FOREIGI		TDOCUMENTS		1	
EXAMINER	DOCUMENT	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION
INITIAL	NUMBER 0, 068,669	7/6/83	EPO		546	31.1	YES NO
agno	0,427,480	5/15/91	EPO			19	
mc.		<u> </u>	EPO		546	344	
3 Mrs	0,455,006	7-1/6/91		TONTAN	546	814	
MAR	1,565,080	4/16/80		T BRITAIN	546	344	
De	1,108,577	4/3/68		TBRITAIN	544	341	
50-0				ng Author, Title, Date, Per Medicinal Chemistry, Vo			-/
15W2		A. Laisen, etc	ai, Journa	i Medicinal Chemistry, vo	n. 10, 3 pg. 402	.412 . 1/	Yél
	14						
-							
		-		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			
EXAMINER	ZNOird			DATE CONSIDERED)5		8

Page 1 of 2	THE UNITED ST	25 2x 7-27-94 IVORTH	INGTON AND TRADEMARK	PATENT Case No. <u>197</u>	00185 # 3
Applicants: MR	CHAEL H. FISHER, ET	JUL JUL 1994	Art Unit: 1205	- C M	8/12/94 -& W
Filed: April 26,			Examiner: Z. DA	ivis X 名シン	
BETA3 A	UTED SULFONAMIDES GONISTS FOR THE TRI ES AND OBESITY		¢.	SP: 120	M 9 th
The Honorable Washington, D.0	Commissioner of Pa C. 20231	tents and Tradem	arks		

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

1. Applicant(s) submit(s) on the attached PTO-1449 herewith a list of patents, publications or other information of which they are aware, which they believe may be pertinent to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. If the captioned case is a continuing application of an earlier filed parent application, the Examiner is respectfully requested to refer to any art cited to the earlier filed parent application.

> I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

page 2 of 2



PATENT Case No. 19203

INFORMATION DISCLOSURE STATEMENT

4. Copies of the following references listed on PTO-1449 are not enclosed because they

have been submitted in a related application as follows:

	RELATED APPLICATION							
REFERENCE	SN	FILING DATE	WERCK CASE					
	1		9.1					
3 g			P. P.					
11 E			1 2					
			07					
			Y					

5. In accordance with 37 C.F.R. 1.97, (check one)

 \square the attached information is filed within three months of the filing date of the captioned case.

- the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

BY: MOLLIE M. YANG

Attorney For Applicant(s) Reg. No. 32,718 MERCK & CO., INC. Patent Dept. P.O. Box 2000

Rahway, N.J. 07065-0907 (908)594- 6343

Date: July 26, 1994



PATENT

Art Unit:1203

Examiner:Da

216 99

0

4/A 11/15

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:Michael Fisher et alSerial No.:08/233,166Case No.: 19203Filed:April 26, 1994For:Substituted Sulfonamides as Selective β3Agonists for the Treatment of Diabetes and
Obesity

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R.1.111

Sir:

There is an outstanding Office Action mailed August 5, 1994 for which a response is due by November 7, 1994. Reconsideration of the application is respectfully requested in view of the following remarks.

REMARKS

Status of the Claims

Claims 1-16 are pending in the application. Claims 5-6 have been withdrawn from consideration.

Election of Species

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

Date: 11/4/94 By: Meller





Serial No.: 08/233,166 Case No.: 19203 Page No.: 2

Applicants hereby affirmed the election of the compound of Example 25. Claims readable thereon are 1-4, 7-16.

Improper Markush Group

Claims 1-4 and 7-16 stand rejected as allegedly being drawn to improper Markush group. Applicants respectfully disagree.

The guidelines set forth in M.P.E.P §706.03(y) for examining Markush-type claims states that "[w]here a Markush expression is applied only to a portion of a chemical compound, the propriety of the grouping is determined by a consideration of the compound as a whole, and does not depend on there being a community of properties in the members of the Markush expression." In the instant case, the claimed compounds <u>as a</u> <u>whole</u> possess a common utility, that as β 3 agonists, and a common core, that of an N-phenylsulfonamide in which the phenyl group is linked to a β hydroxyethanamino group via a linker.


In <u>In re Harnisch</u> 206 U.S.P.Q. 300 (C.C.P.A. 1980) - a case cited by the Examiner, the claimed compounds all had a common function (dyestuffs) and a common core (coumarin), and there the Court held that under the circumstances, the Markush groupings were proper even though the substituents on the coumarin core varied widely. As the facts in the instant case are analogous to those in <u>Harnisch</u>, a similar conclusion of proper Markush groupings must also be reached here.

Applicants respectfully submit that the improper Markush grouping rejection is untenable and request its withdrawal. Applicants further urge that the Examiner adhere to the examination guidelines set forth in M.P.E.P. §803.02 in the examination of the Markush-type claims.

The Examiner indicates that amending the claims to the examined subject matter would overcome the improper Markush rejection. The examined subject matter is said to be as follows:

"A compound having the formula I





where


A is pyridinyl;

 R^7 is Z-(R^{1a})n;

R^{1a} is R¹, C3-C8 cycloalkyl, phenyl;

Z is phenyl, naphthyl.

The radicals not recited above are as defined in claim 1." Regrettably, Applicants cannot so amend the claims as the above definition of R^{1a} does not encompass the elected species, which is the compound having the structure <u>1</u>



The substituted imidazolidone moiety of structure $\underline{1}$ is not embraced by the above-defined R^{1a} .

Objection/Rejection Under 35 U.S.C. §112, first paragraph

The specification is objected to and claims 1-4 and 7-16 are rejected as allegedly failing to adequately teach how to make the claimed invention. Applicants respectfully traverse.



It is well established that a "specification disclosure which contains teaching of manner and process of making and using the invention in terms corresponding in scope to those used in describing and defining subject matter sought to be patented must be taken as in compliance with enabling requirement of first paragraph of 35 USC 112 unless there is reason to doubt objective truth therein which must be relied on for enabling support.....[I]t is incumbent upon the Patent Office, whenever a rejection on this basis is made, to explain why it doubts the truth or accuracy of statement in supporting disclosure and to back up assertions of its own with acceptable evidence or reasoning which is inconsistent with contested statement." In re Marzocchi, 169 U.S.P.Q. 367, 369, 370 (C.C.P.A., 1971).

In the present case, the specification on pages 10-26 provides detailed teachings on how to make the compounds of the present invention in terms corresponding to those used in the claims, and the Examiner has failed to put forth any evidence or reasoning to support the rejection under 35 USC §112, first paragraph. Bare assertion of non-enablement without more is insufficient to sustain this ground of rejection under the prevailing legal standard.

The Examiner states that

A hypothetical compound can be embraced by the claim 1 definition, for instance, if A is pyridinyl, Z is benzene fused to a pyridinyl, R1a is pyridinyl and n is 5. The specification does not adequately teach how to prepare such a bulky compound. Undue experimentation would be involved to prepare such a compound.

The Examiner has imposed an impossible, and erroneous, standard of enablement by implicitly requiring the specification disclosure to teach <u>each and every</u> possible species within the generic claim. Applicants respectfully submit that it is not a function of the claims to specifically exclude possible inoperative substances (see e.g. <u>Atlas Powder v. DuPont de Nemours</u>, 224 USPQ 409, 414 (CAFC 1984)); in fact it would be impossible to do so. Since the claims are addressed to persons skilled in the art, compliance with the enablement requirement must be determined from that perspective. As the Patent Office Board of Appeal has said "[I]t is always possible to theorize some combination of circumstances which would render a claimed composition...inoperative, but the art-skilled would assuredly not choose such a combination." (<u>Ex Parte Cole</u> 223 USPQ 94, 95, 96





(POBA, 1983)). Therefore, even though the Examiner can come up with "hypothetical" compounds, a person skilled in the art would know to avoid those compounds.

In view of the above arguments, Applicants respectfully submit that the objection to the specification, and rejection of the claims under 35 USC§112, first paragraph are in error, and request that the Examiner withdraw the same.

Applicants acknowledge that the references in FORM PTO-892 dated 7/20/94 are cited by the Examiner to show the state of the art, and do not anticipate or render obvious the examined subject matter.

Applicants believe that the application is now in condition for allowance. An early favorable action is respectfully requested.

Respectfully submitted,

By /

Mollie M. Yang Reg. No. 32,718 Attorney for Applicants Merck & Co., Inc. P.O. Box 2000 Rahway, NJ 07065-0907 (908) 594-6343

Date: November 4, 1994

ashington, D.	r f Patents and Trademar C. 20231	ks	In reapplication of: M	i-	T AL	
			Serial No. 08/233,16 Filed April 26, 1994			
			Group Art Unit 1203			
			Examiner DAVIS		()	
No additio	ewith is an amendment nal fee is required. as been catculated as si		OBESITY		1007÷ 120	四月 昭
(1)	(2) Claims remaining after amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	(7) Additional fee
al Claims	` 16	-	** 20 =	0 _ X	\$22	
lependent	•1		*** 3 =	<u>o x</u>	\$76	= 0.00
laims Itiple Iependent Ialms				0	\$240****	= 0.00
			TOTAL ADDITIONAL F	EE FOR THIS AM	INDMENT	0.00
** If the "Hi *** If the "Hig *** Add this i	ghest Number Previous ghest Number Previously lee only if application is ple dependent claims we	ly Paid y Paid amend are orig	entry in Column 4, write "(For" in this space is less For" In this space is less the ed to include multiple dep inally filed. ccount No. 13-2755. Ple	than 20, write "20" in han 3, write "3" in th pendent claims (reg	is space. ardless of nu lltional fees (mber) and

	Malle 8	CO., INC.	
By_			V
Date_	1141	941	0

IN TRIPLICATE REV. 10/1/94 Attorney for Applicant(s) Reg. No. 32,718 MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907

(908)594- 6343 Date: November 4, 1994



PATENT CASE NO. 19203

:

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents and Trademarks Washington, D.C. 20231 In reapplication of: MICHAEL FISHER, ET AL

Serial No.	08/233,166
	And a line of the

Filed April 26, 1994

Group Art Unit 1203

Examiner DAVIS

For: SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA-3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Transmitted herewith is an amendment in the above-identified application.

No additional fee is required.

The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims remaining after amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	(7) Additional fee
Total Claims Independent Claims Muttiple Dependent Claims	* <u>16</u> * <u>1</u>	-	** <u>20</u> = *** <u>3</u> =	0 X 0 X 0	\$22 \$76 \$240****	$= \frac{0.00}{0.00}$ $= \frac{0.00}{0.00}$
			TOTAL ADDITIONAL F	EE FOR THIS AME	NOMENT	0.00

* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Pald For" in this space is less than 20, write "20" in this space.

*** If the "Highest Number Previously Pald For" In this space is less than 3, write "3" in this space.

** Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ 0.00 to Deposit Account No. 13-2755. Please charge any additional fees or credit

overpayment to Deposit Account No. 13-2755. Duplicate copies of this sheet are enclosed.

hereby certify that this correspondence is being deposited with the United States Postal Service as first class malt in an envelope addressed to: Commissioner of Patents and Irademarks, Wash-Ington, D.C. 20231, on the date sppearing below. MERCK & CO., UNC.

By Date

IN TRIPLICATE REV. 10/1/94 Respectfully,

By: Mollie M. Yang Attorney for Applicant(s) Reg. No. 32,718

MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908)594- 6343 Date: November 4, 1994

1924 CAURIENS	IN THE UNITED	STA	TES PATENT AN	TRADEMAR	K OFFIC	E
and the second se	f Patents and Trademar C. 20231	ks	In re application of: <u>N</u> Serlai No. 08/233,16		TAL	
			Filed April 26, 1994			
			Group Art Unit 1203			
			Examiner DAVIS		63	10
			OBESITY		5	4.
No additio	ewith is an amendment nal fee is required. Is been calculated as si		above-identified application		UP: 120	4 83 8 07
No additio	nal tee is required.		above-identified application		(6) Rate	22
No additio The fee he	nal fee is required. as been calculated as si (2) Claims remaining	hown b	above-identified application below. CLAIMS AS AMENDEI (4) Highest Number) (5) Present	(6)	(7) Additional
No additio The fee he (1) tal Claims idependent	nal fee is required. Its been calculated as si (2) Claims remaining after amendment	(3)	above-identified application below. CLAIMS AS AMENDED (4) Highest Number Previously Paid For	0 (5) Present Extra	(6) Rate	(7) Additional
No additio	(2) (2) Claims remaining after amendment	hown b	above-identified application below. CLAIMS AS AMENDED (4) Highest Number Previously Paid For == 20=	0 (5) Present Extra 0X	(6) Rate \$22	(7) Additional fee = 0.00

If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space. Add this fee only if application is amended to include multiple dependent claims (regardless of number) and

no multiple dependent claims were originally filed.

Charge \$ 0.00 to Deposit Account No. 13-2755. Please charge any additional fees or credit

overpayment to Deposit Account No. 13-2755. Duplicate copies of this sheet are enclosed.

I hereb	y cartify that this correspondence is being
Deposit first cl	ed with the United States Postal Service as lass mail in an envelope addressed to:
Comm	issioner of Patents and Trademarks, Wash-
* giph	D.C. 20231, on the date appearing below.
By	Ralle, A-V

Date

IN TRIPLICATE REV. 10/1/94

Respectfully,

Mollie M. Yang By: Attomey for Applicant(s) Reg. No. 32,718 MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908)594- 6343 Date: November 4, 1994

n2/222 166			Patent and	Trademark Off	MENT OF COMMERCE
SERIAL NUMBER	FILING DATE	FIRST N	AMED INVENTOR		ATTORNEY DOCKET NO. MU
08/230,166	5 04/26/94	FISHER			19213 XAMINER
MOLLIE M. PATENT DEF MERCK & CC P. C. BOX 2 PAHMAY, NO The second science of path M	YT. 0., ΣΝΟ. 2009 0706-5-0907 не exeminer in charge of your	1.2M2/0	1202	ART UNIT	PAPER NUMBER
This application has be A shortoned statutory perio		Responsive to comm	TAN F		This action is made linel,
Part II SUMMARY OF	Now to Effect Drawing Chu ACTION	anges, PTO-1474,	B. []		are pending in the application.
2. 🗌 Cleims					have been cancelled.
3. 🗍 Claims					are allowed.
4. 🗋 Cleims					sre rejacted.
5. 🛛 Claims					are objected to.
5. Cialma 1-1	Q			are subject to restrict	tion or election requirement.
	has been filed with inform a are required in response			ire acceptable for ex	emination purposee.
	r exhatiliute drawings have able. 🗋 not ecceptable (F.R. 1.84 lheen drawings
	dditional or substitute she lisapproved by the examin			has (have) been	approved by the
11. 🔲 The proposed de	rewing correction, Nied on	1	, has been 🗖 ap	provad. 🗌 disappr	oved (see explenation).
이 아님이 아이지 않는 것이 아파가 가 많이 많이 가지?					oelved 🔲 not been received
13. 🔲 Bince this applic	3 (03) H	ndition for allowance	except for formal m		s to the merits is closed in
14. Other			10-100-100-000 0		

Serial No. 08/233,166 Art Unit 1203

Part III DETAILED ACTION

 Pursuant to Applicant's remarks based on the improper Markush group and election of species, restriction is now required.

-2-

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

I. Claims 1, 2, 5, and 7-16, drawn to compounds, composition, and method of use wherein A represents phenyl or a benzene fused to a C_3 - C_8 cycloalkyl ring.

II. Claims 1-4 and 7-16, drawn to compounds, composition, and method of use wherein A represents a 5 or 6-membered heterocyclic ring with from 1 to 4 heteroatoms selected from oxygen, sulfur, and nitrogen, a benzene ring fused to a 5 or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur, and nitrogen, or a 5 or 6membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur, and nitrogen fused to a 5- or 6-membered heterocyclic ring with from 1 to 3 heteroatoms selected from oxygen, sulfur, and nitrogen. Serial No. 08/233,166 Art Unit 1203

The inventions are distinct, each from the other because of the following reasons:

-3-

The radicals within the definition of A are diverse in scope. A prior art reference which anticipates one member of A such as phenyl under 35 USC 102 would not render obvious another member such as pyridinyl under 35 USC 103. Accordingly, the radicals are independent and patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

A telephone call was made to Ms. Mollie Yang on January 23, 1995 to request an oral election to the above restriction requirement, but did not result in an election being made. Serial No. 08/233,166 Art Unit 1203

2. Applicant is reminded that upon the cancellation of claims to a nonelected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

-4-

A facsimile center has been established in Group 1200, room 3C10. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or 305-3592.

Any inquiry concerning this communication should be directed to Zinna

N. Davis at telephone number (703) 308-4699.

Zunna N. Davis Fatent Examiner Group 1200- ART UNIT 1203

DAVIS:jd January 27, 1995

U.S. DEPARTMENT OF COMMERCE PATENT AND THADEMARK OFFICE **ONLINE SEARCH REQUEST FORM** ********* SERIAL NUMBER . 08/133.166 Zinna N. DAVIS USER ART LINIT 1203. PHONE XALGAG DATE 77-94 Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known. You may include a copy of the broodest and or relevant claim(s). $H = \frac{R}{1-CH_2 - N - C - (K)_m} \left(= \frac{1}{1-N} - \frac{1}{N} - \frac{1}{S(0)} \left(\frac{CH_2}{2} + R^2 - \frac{1}{N} \right) \right)$ A = carbocyclic/heterocyclic $X = CH_2-/-CH_2CH_2-/-CH=CH-/-CH_2O$ m= Dor 1 n= 0-5 r=0-3 R7 - Z2(R'2) Z = carbocylic/heterocyclic R^{1a}->open ************ STAFF USE ONLY a SYSTEMS CAS ONLINE COMPLETED idaly DARC/QUESTEL SEARCHER DIALOG TOTAL TIME UNLINE TIME 10 SDC in memory OTHER NO. OF DATABASES Page 83 of 108

FILE 'MEDLINE' L9 0 L6

12 30

FILE 'EMBASE' L10 0 L6

TOTAL FOR ALL FILES L11 0 L6

=> fil ca;s 16/p;s 16/d FILE 'CA' ENTERED AT 12:14:22 ON 08 JUL 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 25 Jun 1994 (940625/ED) VOL 120 ISS 26

To help control your online searching costs, consider using the HCA File when conducting SmartSELECT searches with large numbers of terms.


THIS IS THE BETTER CA FILE. SEE NEWS FOR DETAILS.

L12 1 L6/P

L13 0 L6/D

=> s 112 not 17

L14 0 L12 NOT L7



Page 85 of 108

.

()

VAR G2=H/C REP G3=(0-3) CH2 VPA 14-4/5/6 U NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE L6 2 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 8814 ITERATIONS ANSWERS SEARCH TIME: 00.00.48

L6 ANSWER 1 OF 2 REGISTRY COPYRIGHT 1994 ACS RN 25233-68-5 REGISTRY CN Benzamide, 5-chloro-N-(o-chloro-.beta.-hydroxyphenethyl)-2-ptoluenesulfonamido- (7CI, 8CI) (CA INDEX NAME) FS 3D CONCORD

- MF C22 H20 C12 N2 04 S
- LC STN Files: BEILSTEIN*, CA, CAOLD, IFICDB, IFIPAT, IFIUDB (*File contains numerically searchable property data)



 $\begin{array}{c} R^2 = H \\ R^3 = H \end{array} \qquad \neq \begin{array}{c} 0 \\ C \end{array}$


2

1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: P 71:81338

L6 ANSWER 2 OF 2 REGISTRY COPYRIGHT 1994 ACS

RN	23595-56-4 REGISTRY
CN	Benzamide, N-(o-chlorobetahydroxyphenethyl)-o-(p-
	toluenesulfonamido) - (8CI) (CA INDEX NAME)
FS	3D CONCORD
MF	C22 H21 C1 N2 O4 S



FILE 'CA' ENTERED AT 12:13:00 ON 08 JUL 94 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 1994 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 25 Jun 1994 (940625/ED) VOL 120 ISS 26

To help control your online searching costs, consider using the HCA File when conducting SmartSELECT searches with large numbers of terms.

THIS IS THE BETTER CA FILE. SEE NEWS FOR DETAILS.

L7 1 L6

=> d .mh

L7	ANSWER 1 OF 1 CA COPYRIGHT 1994 ACS
TI	Tranquilizer N-[o-(2-oxazolin-2-yl)phenyl] alkyl or aryl sulfonamides and intermediates
SO	U.S., 5 pp. CODEN: USXXAM
IN	Santilli, Arthur A.; Osdene, Thomas S.
PI	US 3452037 690624
AI	US 631213 - 661003
PY	1969
AB	Prepd. from I are the title compds. (II) having
tran I an	equilizer, antidepressant, anticonvulsant, and analgesic activities.

Sa _ 4

prepd. from an isatoic anhydride. Thus, 9.85 g. 5-chloroisatoic anhydride (III) and 4 g. HOCH2CH2NH2 heated in 50 ml. H2O at 100.degree. for 20 min. gave 1 (A = R = H, X = Cl) (IV), m. 121-2.5.degree. (H2O). Addn. of 10.3 g. 4-Me-C6H4SO2Cl in portions to 5.8 g. IV in 30 ml. dry pyridine at 0.degree. and, after standing in the cold overnight, addn. of H2O gave 9.6 g. solid, m. 112-19.degree.. This was heated with 30 ml. EtoH over steam to give II (A = 4-MeC6H4SO2, R = H, X = Cl), m. 174-6.degree. (EtOH) . Thus prepd. were the following II (A, R, X, m.p., and yield % vield given): Ph, H, H, 66-8.degree. (aq. EtOH), -; MeSO2, H, H, 164-5.degree. (benzene), -; MeSO2, Me, Cl, 114-16.degree. (aq. EtOH), 24; MeSO2, Ph, Cl, 157-8.degree., 83; PhCH2SO2, Ph, C1, 139-40.degree. (cyclohexane), 80 (crude); 4-MeC6H4SO2, H, H (V), 197-9.degree. (EtOH), -; 4-MeC6H4SO2, Me, Cl, 122-4.degree. (MeOH), 16 (50% crude); 4-MeC6H4SO2, Ph, Cl, 132-3.degree. (MeOH), 100 (crude); 4-MeC6H4SO2, 2-C1C6H4, H, 152-3.degree. (EtOH), 79 (crude); 4-MeC6H4SO2, 2-ClC6H4, Cl, 167-8.degree. (benzene-petroleum ether), 40. V (1 g.) and 1 g. P2S5 after 2 hrs. reflux in 15 ml. dry pyridine, hydrolysis (50 ml. hot H2O), and neutralization (30% HC1) gave N-[o-(2-thiazolin-2-y1)pheny1]-p-toluenesulfonamide, m. 160-3.degree. (aq. pyridine). Intermediate I described were (A, X, R, and m.p. given): Ph, H, H, 77-9.degree. (benzene-cyclohexane); H, Cl, Me, 109-10.5.degree. (benzene); H, Cl, Ph, 119-21.degree. (benzene). Addnl. prepns. were given. Thus, refluxing 2 hrs. of 134 g. 2-ClC6H4CH(OH)CN and 82 g. Ac20 gave 107 g. 2-C1C6H4CHOAcCN, b0.cntdot.25 110-1.degree., which was added dropwise to 37.8 g. LiAlH4 stirred in 800 ml. anhyd. tetrahydrofuran. Reflux (2 hrs.), dropwise addn. of 100 ml. H2O and then 200 ml. 20% NaOH, and work up

. . . .

 \bigcirc

on the next day gave 56 g. 2-ClC6H4-CH(OH)CH2NH2 (IIIa), b0.cntdot.25 108-12.degree.. Mixts. of IIIa (18.9 and 18.8 q., resp.) with 19.7 g. III or 16.3 g. isatoic anhydride, both in 50 ml. EtOH, heated 15 min. gave, resp., the I (A = H, R = 2-ClC6H4) (Ia), (X = H), m. 103-5.degree. (benzene.cyclohexane) and Ia (X = Cl), m. 105-7.degree. (benzene.cyclohexane), N-(p-toluenesulfonyl deriv. (by action of 2 equiv. 4-MeC6H4SO2Cl in abs. pyridine overnight at 0.degree., crude yield 78%) m. 165-6.degree. (benzene). The last was converted to the corresponding oxazoline I (above) by the action of MeSO2C1. Alternately, refluxing a soln. of 3.4 g. 2,5-(H2N)ClC6H3CONHCH2CH2OH in 25 ml. SO2Cl2 for 1 hr., evapn., and treatment of crude product (3 g.) in 10 ml. hot H20 with 10% Na2CO3 gave 2,5-(H2N)ClC6H3CONHCH2CH2Cl (IIIb), m. 115-16.degree. (cyclohexane). Addn. of 4 g. finely powd. Na2CO3 to 6.2 g. IIIb in 15 ml. Me2NCHO and heating at reflux 1.5 hrs. gave 3.2 g. II (A = R)= H, X = Cl), m. 76-8.degree. (hexane). Also described was the prepn. (reflux of 5 g. 2-PhNHC6H4C02H in 20 ml. Et02CCl for 10 hrs.) of N-phenylisatoic anhydride, m. 177-9.degree. (EtOH). => d an L7 ANSWER 1 OF 1 CA COPYRIGHT 1994 ACS 71:81338 AN CA => fil .biotech;s 16 FILE 'BIOSIS' ENTERED AT 12:13:29 ON 08 JUL 94 COPYRIGHT (C) 1994 BIOSIS(R) FILE 'MEDLINE' ENTERED AT 12:13:29 ON 08 JUL 94 FILE 'EMBASE' ENTERED AT 12:13:29 ON 08 JUL 94 COPYRIGHT (C) 1994 Elsevier Science B.V. All rights reserved. FILE 'BIOSIS' 0 L6

 $\mathbf{L8}$

=> d 13 que sta d 16 que stat; d 16 1-2 id. :an; fil ca; s 16 TR J33!66



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Michael Fisher et al	4	
Serial No.:	08/233,166	Case No.: 19203	Art Unit:1203
Filed:	April 26, 1994		Examiner:Davis
For:	Substituted Sulfonan Agonists for the Trea	nides as Selective β3 atment of Diabetes and	19
	Obesity		

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

RESTRICTION REQUIREMENT

Sir:

There is an outstanding Office Action mailed February 2, 1995 for which a response is due by March 2, 1995. Kindly amend the application as follows:

In the Claims:

AMEND the following claims

Claim 1, page 42, line 17: after "A is" delete "phenyl, ".

Claim 1, page 42, line 19: after "nitrogen" delete "a benzene ring fused to a C3-C8 cycloalkyl ring".

Claim 2, page 44, line 4: after "A is" delete "phenyl, or ".

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

____ Date: 2/28/95-By: Udlie -

Claim 7, page 46: delete the lines 33 to 34 (i.e. the last and penultimate lines on page 46).

Claim 7, page 47: delete lines 1-4.

CANCEL claims 5 and 6.

REMARKS

The claims have been restricted as follows:

Group I: claims 1, 2, 5 and 7-16 drawn to compounds, compositions, and method of use wherein A represents phenyl or a benzene fused to a C3-C8 cycloalkyl ring.

Group II: claims 1-4 and 7-16 drawn to compounds, compositions, and method of use where A represents a hetercyclic moiety as defined in the claims.

Applicants hereby elect the invention of Group II without traverse. In accordance with this election claims 1, 2 and 7 have been amended, and claims 5 and 6 have been canceled.

Applicants believe that the application is now in condition for allowance. An early favorable action is respectfully requested.

Respectfully submitted,

Mollie M. Yang

Reg. No. 32,718 Attorney for Applicants Merck & Co., Inc. P.O. Box 2000 Rahway, NJ 07065-0907 (908) 594-6343

Date: February, 28, 1995

r,

1995 B	IN THE UNITED	STA	TES PATENT AN	D TRADEMARK		0. 19203
11. CHARGE	f Patents and Tradema C. 20231	rks		36	S SELECT	
No addition	ewith is an amendment nal fee is required. Is been calculated as s		above-identified applications below. CLAIMS AS AMENDE		10-14 120	約10 部 7 53
(1)	(2) Claims remaining after amendment	(3)	(4) Highest Number Previously Pald For	(5) Present Extra	(6) Rate	(7) Additional fee
otal Claims ndependent Claims fuitiple Dependent Claims	* 14 * 1	• •	** <u>16</u> *** <u>1</u>	0 X 0 X	\$22 \$76 \$240****	$= \frac{0.00}{0.00}$ $= \frac{0.00}{0.00}$
SPEAK I BP			TOTAL ADDITIONAL F	EE FOR THIS AME	NDMENT	0.00
** If the "Hig *** If the "Hig **** Add this fo no multip Charge \$	hest Number Previous hest Number Previous ee only if application is ble dependent claims we 0.00 to De	sly Paid y Paid amend ere orig	entry in Column 4, write "C For" in this space is less t For" in this space is less t led to include multiple dep inally filed. ccount No. 13-2755. Plea 3-2755. Duplicate copies	than 20, write "20" in han 3, write "3" in this penident claims (regar ase charge any addit	space. Idless of nu	

Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date appearing below. MERCK & CO., INC. By

IN TRIPLICATE REV. 10/1/94
 Attorney
 for Applicant(s)

 Reg. No.
 32,718

 MERCK & CO., INC.

 Patent Dept.

 P.O.
 Box 2000

 Rahway, N.J.
 07065-0907

 (908)594 6343

 Date:
 February 28, 1995

G T	-				PATENT CASE N	O. <u>19203</u>
Ser la	' f Patents and Trademar		TES PATENT AN In re application of: M Serial No. 08/233,10 Filed April 26, 1994 Group Art Unit 1203 Examiner DAVIS	NICHAEL FISHER, E		E
No additio	ewith is an amendment nal fee is required. as been calculated as s		AGONISTS FO OBESITY above-identified applicati velow.		OF DIABE	
(1)	(2) Claims remaining after amendment	(3)	(4) Highest Number Previously Pald For	(5) Present Extra	(6) (6) Rate	(7) Ağditional fee
Total Cialms Independent Cialms Multiple Dependent Cialms	* <u>14</u> • <u>1</u>	-	** <u>16</u> = *** <u>1</u> =	0 X 0 X 0 X	\$22 \$76 \$240****	$= \frac{0.00}{0.00}$ = 0.00
			TOTAL ADDITIONAL F	EE FOR THIS AME	NDHENT	0.00

* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.

**** Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ 0.00 to Deposit Account No. 13-2755. Please charge any additional fees or credit

overpayment to Deposit Account No. 13-2755. Duplicate copies of this sheet are enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to; Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the data appearing below. MERCK & CO., INC.

By Date.

IN TRIPLICATE REV. 10/1/94 Respectfully,

By: Mollie M. Yang U Attorney for Applicant(s) Reg. No. 32,718

MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908)594- 6343

Date: February 28, 1995

ROOM	PATENT CASE NO. 19203
$\begin{pmatrix} AB \\ G \\ B995 \end{pmatrix}$ in the United St	ATES PATENT AND TRADEMARK OFFICE
mmissioner of Patents and Trademarks shington, D.C. 20231	In re application of: MICHAEL FISHER, ET AL Serial No. 08/233,166
•	Filed April 26, 1994
	Group Art Unit 1203
	Examiner DAVIS
	For: SUBSTITUTED SULFONAMIDES AS SELECTIVE B3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

X No additional fee is required.

П The fee has been calculated as shown below.

CLAIMS AS AMENDED

(1)	(2) Claims remaining after amendment	(3)	(4) Highest Number Previously Paid For	(5) Present Extra	(6) Rate	(7) Additional fee
Total Claims Independent Claims Multiple Dependent Claims	* <u>14</u> * <u>1</u>		** <u>16</u> = *** <u>1</u> =	0 X 0 X 0	\$22 \$76 \$240	= 0.00 = 0.00 = 0.00
_			TOTAL ADDITIONAL F	EE FOR THIS AME	DMENT	0.00

" If the entry in Column 2 is tess than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Paid For" in this space is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" in this space is less than 3, write "3" in this space.

**** Add this fee only if application is amended to include multiple dependent claims (regardless of number) and no multiple dependent claims were originally filed.

Charge \$ 0.00 to Deposit Account No. 13-2755. Please charge any additional fees or credit

overpayment to Deposit Account No. 13-2755. Duplicate copies of this sheet are enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Wash-ington, D.G. 20231, on the data appearing below. MERCK & CO., INC.

By. Date .

IN TRIPLICATE REV. 10/1/94

Respectfully

Mollie M. Yang By: Attorney for Applicant(s) Reg. No. 32,718 MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908)594- 6343 Date: February 28, 1995

3



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

SERIAL	NUMBER	FILING DATE	FIRST NAMED APPLICANT	AT	TORNEY DOCKET NO
L	08/233.	konsutto - o an a la anar ara	4 FISHER	M	19233
	114172009	100 0472075		(3.5)	
		5		NORTHN	NAMEN DAVI,
	الارقار المصارية	NAME.	1201/0327		N:
	MOLLIE PATENT				
		2 CO., INC.			PAPER NUMBER
		0X 2000	10000	1203	ŀ
	RAEWAY,	, NJ 07065-€9	107		03/27/98
 				DATE MAILED;	
32 - 22					
		N	OTICE OF ALLOWABILITY		
19					
ART C		4			
This co	mmunication	is responsive to AME		xry 28, 1990	<u>`````````````````````````````````````</u>
. De Als the	claims being	allowable, PROSECUTIO	IN ON THE MERITS IS (OR REMAINS) Nowance And Issue Fee Due or other op	CLOSED in this application of the communication of	ation. If not included
Course.		1-4 and	7-16 (may 1)-14 100	montivest.)	
12	wed claims a			permery	
	wings tiled ó uladament is:		nority under 35 U.S.C. 119. The certifie	d copy has [] hoon re	ceived. [] not been
			arlai No, filed		
		xaminer'a Amendment.			
* 1 <u>22</u> Sector States		xeminer interview Summar	The transmission of the transmission of the second s		
S. C. S. S. S. S. S. S. S. S.		xaminer's Statement of Rep on the religious of the			
· · · ·		OTICE OF HEFEHENCES O IFORMATION DISCLOSUR			
	6 sulscned in	IF CHIMATION DISLECTSON	E OTATION, PTO-1448.		
ABT II.					
			SE to comply with the requirements not		
		D' indicated on this for blained under the provisio	m, Failure to timely compty will result ns of 37 CFR 1.136(a).	in the ABANDONMENT	o! this application.
□ Note the	ettached E	XAMINER'S AMENDMENT	OF NOTICE OF INFORMAL APPLICATI	ON, PTO-152, which di	closes that the osth
or declar	ation is delic	sient. A SUBSTITUTE OATH	I OR DECLARATION IS REQUIRED.		
OF THIS		AKE THE DRAWING CHA	ANGES INDICATED BELOW IN THE MA	NNER SET FORTH ON	THE REVERSE SIDE
		rtics are indicated on th	ONOTICE HE PATENT DRAWINGS, P	TO-948, allached here	to or 10 Papar No.
A CONTRACTOR OF THE OWNER		RECTION IS REQUIRED.			DODECTION
	INCOSCI DIS INCO.	awing correction filed on .	hæs been a	ipproved by the examin	Br. COHRECTION IS
	oved drawing	g correctiona are describe	ed by the exeminer in the attached EX	AMINER'S AMENDMEN	IT. CORRECTION IS
d. 🛛 Forma	al drawings a	re now REQUIRED.			
			per right hand corner, the following info		CE OF ALLOWANCE
VD ISSUE FE	e due: ISSU	E BATCH NUMBER, DATE	OF THE NOTICE OF ALLOWANCE, AND	SERIAL NUMBER	
techmente:					
Examiner's An		Bernet BTOL 411	Notice of Informal Application Notice to Retent Drawing		
Examiner Inter Reasons for Al		Pacord, PTOL- 413	 Notice re Patent Drawings Listing of Rended Drafter 		
Notice of Rele	rences Ched. P		Other		
Information De	sofosure Criaik	an. PTO-1449			
			9		
1			~1	T	-
YILLANDA				· · · · ·	
nour			Cuan	~~~~	
703)308	-400	*	U.Water	Ny 1	
170airs 703)308	-4699		C. Vrasen Supervisory Patent Group 12	Examine	

.

P1CL-37 (REV. 4-89) *

USCOMM DC 59-3769



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

SERIAL NUMBER FILING DATE	FIRST NAMED APPLICANT		ATTORNEY DOCKET N
08/233,166 04/26/94	FISHER	М	19203
	75F1/0817 [EXAMINER
MOLLIE M. YANG		1010000000000	
PATENT DEPT.		ART UNIT	NGTON DAVI,Z
MERCK & CO., INC. P.O. BOX 2000		ARTUNI	PAPER NUMBER
RAHWAY, NJ 07065-090	7	120	3
	0	ATE MAILED:	8/17/95
		U	0/1//30
	NOTICE OF ABANDONMENT		
white an effective to a second second second	v of:		
This application is abandoned in view			
	o the Office letter, mailed		
1. Applicant's failure to respond to			
 Applicant's failure to respond to Applicant's letter of express aba 	o the Office letter, mailed	7 C.F.R. 1.138.	
 Applicant's failure to respond to Applicant's letter of express aba Applicant's failure to timely fill in the Office letter. 	o the Office letter, mailed andonment which is in compliance with 3	7 C.F.R. 1.138.	thin the period set
 Applicant's failure to respond to Applicant's letter of express aba Applicant's failure to timely fill in the Office letter. 	o the Office letter, mailed andonment which is in compliance with 3 le the response received e required issue fee within the statutor of the Notice of Allowance.	7 C.F.R. 1.138.	thin the period set
 Applicant's failure to respond to Applicant's latter of express abay Applicant's failure to timely fill in the Office latter. Applicant's failure to pay the malling date of	o the Office letter, mailed andonment which is in compliance with 3 le the response received e required issue fee within the statutor of the Notice of Allowance.	7 C.F.R. 1.138. 	thin the period set months from the
 Applicant's failure to respond to Applicant's letter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the malling date of	o the Office letter, mailed andonment which is in compliance with 3 le the response received a required issue fee within the statutor of the Notice of Allowance.	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) sue fee if the se, unless it ha	nin the period set months from the , applicant(s) may delay in payment s been previously
 Applicant's failure to respond to Applicant's latter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the mailing date of	o the Office letter, mailed andonment which is in compliance with 3 le the response received e required issue fee within the statutor of the Notice of Allowance. on eceived in Allowed Files Branch as of C. 151, and under the provisions of 37 (to accept the delayed payment of the is on must be accompanied by the issue fe	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) ssue fee if the se, unless it hat fied showing as a new Notice	hin the period set months from the , applicant(s) may delay in payment s been praviously a to the causes of of Allowance and
 Applicant's failure to respond to Applicant's letter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the mailing date of The issue fee was received o The issue fee has not been re in accordance with 35 U.S.C petition the Commissioner to was unavoidable. The petitic submitted, in the amount sp the delay. If applicant(s) never received withdrawal of the holding o 172 U.S.P.Q. 513. Applicant's failure to timely co 	the Office letter, mailed andonment which is in compliance with 3 le the response received a required issue fee within the statutor of the Notice of Allowance. eceived in Allowed Files Branch as of c. 161, and under the provisions of 37 of the accompanied by the issue fe becified by 37 C.F.R. 1.17 (I), and a verified d the Notice of Allowance, a petition for of abandonment may be appropriate in perfect the drawings and/or submit new	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) sue fee if the see, unless it hat fied showing as a new Notice view of Delgar	hin the period set months from the , applicant(s) may delay in payment s been previously s to the causes of of Allowance and inc. v. Schuyler,
 Applicant's failure to respond to Applicant's latter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the mailing date of	o the Office letter, mailed andonment which is in compliance with 3 le the response received a required issue fee within the statutor of the Notice of Allowance. eceived in Allowed Files Branch as of c. 161, and under the provisions of 37 of the delayed payment of the is on must be accompanied by the issue fe becified by 37 C.F.R. 1.17 (I), and a verified the Notice of Allowance, a petition for of abandonment may be appropriate in	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) sue fee if the see, unless it hat fied showing as a new Notice view of Delgar	hin the period set months from the , applicant(s) may delay in payment s been previously s to the causes of of Allowance and inc. v. Schuyler,
 Applicant's failure to respond to Applicant's letter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the mailing date of	 andonment which is in compliance with 3' andonment which is in compliance with 3' le the response received	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) sue fee if the see, unless it hat fied showing as a new Notice view of Delgar	thin the period set months from the applicant(s) may delay in payment s been previously a to the causes of of Allowance and inc. v. Schuyler, ormal drawings by
 Applicant's failure to respond to Applicant's letter of express abay Applicant's failure to timely fill in the Office letter. Applicant's failure to pay the mailing date of	 andonment which is in compliance with 3' andonment which is in compliance with 3' le the response received	7 C.F.R. 1.138. with ry period of 3 C.F.R. 1.316(b) sue fee if the see, unless it hat fied showing as a new Notice view of Delgar	hin the period set months from the , applicant(s) may delay in payment s been previously s to the causes of of Allowance and inc. v. Schuyler,

DIRECT ANY INQUIRIES TO # PUBLISHING DIVISION NARCIA CAMPBELL (703) 305-8190 OR PRISCILLA FULLER (703) 305-8203

PTO-1432 (REV. 5-63)



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: Box ISSUE FEE COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

1	214	ń	11	١.	1	ź	ļ
64	GL 1 -		4.1		~1	1.1	

MOLLIE M. YANG FATENT DEPT. MERCK & CO., INC. P.O. DOX 2000 RAHWAY, NJ 07065-0907 Note attached communication from the Examinar

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

SERIES CODE/SERIAL ND.	FILING DATE	TOTAL CLAIMS	EXAMINER AND GROUP ART UNIT	DATE MAILED
08723	5 100 000	26.794 014	MORTHINGTON DAVI.	1203 03/27
First Named Applicant		(P./ 24)	MACHAGES IN	1.00
TLE OF WENTION SUBSTI	TUTED GULFO	NAMIDES AS S ETES AND OBB	ELECTIVE BETAS AGONISTS	FOR THE
ATTY'S DOCKET	NO, CLASS-SUB	LASS BATCH NO.	APPLN. TYPE SMALL ENTITY FEE	DUE DATE DUE
5 1920	2	514-357.000	KOS UTILITY NO	\$1210.00 06/27Y
PROSECUTION ON THE THE ISSUE FEE MUST E APPLICATION SHALL B HOW TO RESPOND	MERITS IS CLOS DE PAID WITHIN (E REGARDED AS TO THIS NOT	<u>SED.</u> THREE MONTHS S ABANDONED. IC E:	NED AND IS ALLOWED FOR ISSUA FROM THE MAILING DATE OF THIS THIS STATUTORY PERIOD CANNOT	NOTICE OR THIS BE EXTENDED.
Review the SMALL ENT If the SMALL ENTITY is current SMALL ENTITY	shown as YES, v	erify your A	the SMALL ENTITY is shown as NO: . Pay FEE DUE shown above, or . File verified statement of Small Entity	

A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the patent and Trademark Office of the change in status, or

B. If the Status is the same, pay the FEE DUE shown above.

II. Part B of this notice should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B should be completed and returned. If you are charging the ISSUE FEE to your deposit account, Part C of this notice should also be completed and returned.

III. All communications regarding this application must give series code (or filing date), serial number and batch number. Please direct all communication prior to issuance to Box ISSUE FEE unless advised to contrary.

IMPORTANT REMINDER: Patents Issuing on applications flied on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PTOL-85 (REV. 12-93) (0651-0033)

4. PATIENT AND TRADEMARK OFFICE COPY

-		PPLICATIC		ETERMINAT	ION RECO		Application of	-		
1			ive Octobe				03	3	160	0
		the second second second	AS FILED -		lumn 2)	SMALL	ENTITY	OR	OTHER T	1000 000 0 million a
OR	(4 6.)	The second se	R FILED	NUMBER	EXTRA	RATE	FEE		RATE	FEE
ASIC	FEE		90.0	dian .	Jaco	1	\$355.00	OR		\$710.0
OTA	L CLAIMS	16		is 20 = 🔭		x\$11=		OR	x\$22=	
IDE	PENDENT CLA	IMS	min	us 3 = *		x 37=		OR	x 74=	
MU	LTIPLE DEPEN	DENT CLAIM PR	ESENT			+115=		OR	+230=	
l the	difference in colu	mn 1 is less then ze	ro, antar "0" in	column 2		TOTAL		OR	TOTAL	710
		CLAIN (Column 1)	IS AS AME	ENDED - PART I (Column 2)	(Column 3)	SMALL	ENTITY	OR	OTHER T	
AMENUMENI A	51014	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
	Total	*	Minus	**	-	x\$11=		OR	x\$22=	
	Independent	*	Minus	***		× 37=	-	OR	x 74=	
4	FIRST PRE	SENTATION OF	MULTIPLE DI	EPENDENT CLAIM		+ 115=		OR	+230=	
		(Column t)		101	10.1	TOTAL		OR	TOTAL	
		CLAIMS		(Column 2)	(Column 3)	ADDIT. FEE	T	iî	DUIT. FEE	
MENIB		REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
	Total	*	Minus	**	=	x\$11=		OR	x\$22=	
AMENU	Independent	• .	Minus	***	-	x 37=		OR	x 74=	
4	FIRST PRE	SENTATION OF	MULTIPLE D	EPENDENT CLAIM		+ 115=		OR	+ 230=	
		(Column 1)		(Column 2)	(Column 3)	TOTA ADDIT. FE		OR	TOTAL DDIT. FEE	
AMENDMENT C		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER (PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
NDM	Total	*	Minus	**	=	x\$11=		OR	x\$22=	
MEN	Independent	2	Minus	***	-	x 37=		OR	x 74=	
4	FIRST PRE	SENTATION OF	MULTIPLE D	EPENDENT CLAIM		+115=		OR	+230=	
- If 1	he "Highest Nur he "Highest Nur	mber Previously F mber Previously F	Paid For" IN T	olumn 2, write "0" in HIS SPACE is less t HIS SPACE is less t	han 20, enter "20" han 3, enter "3".		E	OR	TOTAL ADDIT. FEE	
ORM	e "Highest Num PTO-875 10-92)	ber Previously P	aid For* (Tota	l or independent) is t	the highest numbe	- and the	a appropriate l	-	NUST IN ADDRESS OF	00000000

ð.

Page 99 of 108

n PTO 11: V 2041) ;				141	PÁC	E DA	TA EN	ITRY	COE	ING	SH	EET	1523	U.S. D	EPAR Patr	MENT and and	OF COI Tradem	MMERC ork Offic	-		MINER	2 / 1 /	ee.	yr	28	DAT	-01-	1201	194
08/	2331	640 4	PPLIC	ATION	NUN	ABER	=			PE		MON				чеар 7Ц				- 1		NIT DIS]	5		4	[SHEET	
i.	- 4 D	[FII	шма 71	G FEE	2	FO		Ē	19	12		NEY D	оскі		JMBĖ	R]	
ONT	STATI	JS	PARE	NT AF			N	ľ.		i-	-	APDI	-	ONTI		-		ion		1	PAF	RENT		ENT			Sec.		. :
CODE		Ī	SE.	TAL		<u>>en</u>		P	c	T	1	APPL	IUA				IMBER		1	1		NUM	DER.		[]	MON	1	DAY	YEA
		-	-	1.1.1				P	C	T	1				-	1		-					+						
				ine.	1	-		P	C	т	1					1	1-1		14		-			1				-	
-					-			P	C	т	1					1			14	1.1		-	-				1		
-		-			(1	P	c	т	1				-	1		-	-			-							
		FORE	ITY	- (COUN	ITRY	241 - 		1	PC					1		FION I		R	I.		MC		FORE	DAT	YEAR			
			}	F			-	F	-		-		-							1-									-++
25		-			-		-	*			+	-	-							8						-		a noer is Nam	-915 GH 444 Y
			100	-	+	-	-		10	+	-		-	-	-	-		1		_							-		1.14

1 3

94° - 16

Page 100 of 108

. .

.

|--|

13 26 N	-	UTED OTH		THE AND	TRADEMANY	2035 - 2235 1941 - 2015 - 2015	33166 Paten
3 1994 AN	THE UN	NITED STA	TES PAIL	ENT AND	TRADEMARK	OFFICE	
omnifisioner ober tent Vashington 1997. 2023	s and Trade 31	emarks			Deposit Acct. 13- MERCK & CO., IN Our Case Docket	IC.	
	20. 1220 - 2423			14 1	Our Gase Docket	NO. 13200	
ransmitted herewith for a patent application of): MICHAEL	H. FISHER	, DONG OK	, ELIZABETH M. I	NAYLOR AND	O ANN E. WEBER
						2.0	
or: SUBSTITUTED S	SULFONAN	AIDES AS SEL	ECTIVE BE	ETA 3 AGO	VISTS FOR THE	TREATMENT	OF DIABETES
AND OBESITY							
AND OBESITY							
AND OBESITY	she	eets of drawin	ıg.				
AND OBESITY			ıg.				
AND OBESITY	f the invent		ıg.				application.
AND OBESITY	f the invent f a Nu		ig. Num Exi		Rate		application. Basic Fee \$710
AND OBESITY nclosed are also: An assignment o A certified copy of For	f the invent f a Nu	nion to	Num		Rate \$22		Basic Fee
AND OBESITY Inclosed are also: An assignment o Acertified copy of	f the invent f a Nu F	tion to mber illed	Num	tra			Basic Fee S710
AND OBESITY Inclosed are also: An assignment o An assignment o For For Inclosed are also:	f the invent f a Nu F 16	tion to Inber filed - 20 =	Num Ex	tra X	\$22		Basic Fee \$710 = 0.00

DATE OF DEPOSIT_APT	AL CENTRONE
EXPRESS MAIL NO. E.G.	29285101508
I MEREBY CERTIFY TH BEING DEPOSITED WITH SERVICE AS EXPRESS ADDRESSEE" BEFORE 5 ENVELOPE ADDRESSED AND TRADEMARKS, WASH	AT THIS CORRESPONDENCE IS I THE UNITED STATES POSTAL
MAILED BY 1000	26, 1994
-	/

REV.6/14/93

Respectfully,

By: Mollie M. Yang

Attorney For Applicant(s) . Reg. No. 32,718

MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908) 594- 6343

Date: April 26, 1994

IN TRIPLICATE

1 -

1				\$230	= 0.00
1				1	= 0.00
1	- 3=	0	х	\$74	_ 0.00
16	- 20 =	٥	х	\$22	= 0.00
				Rate	Basic Fee \$710
ofa					application.
of the inven	ntion to				
st	neets of drawi	ng.			
SULFONA	MIDES AS SE	LECTIVE B	ETA 3 AGO	NISTS FOR THE TREAT	MENT OF DIABETES
					14
or filing is of inventor(s	s): MICHAEI	L H. FISHER	DONG OK	, ELIZABETH M. NAYLO	R AND ANN E. WEBER
•				Our Case Docket No. 1	9203
31				MERCK & CO., INC.	
ts and Trad					
N THE U	INITED STA	TES PATE	ENT AND	TRADEMARK OFFI	233166
	nts and Trac 31 or filing is of Inventor(s SULFONA 	nts and Trademarks IS1 or filing is of Inventor(s): MICHAE SULFONAMIDES AS SE sheets of drawing of the invention to of a Filed	tts and Trademarks IS1 or filing is of inventor(s): MICHAEL H. FISHER SULFONAMIDES AS SELECTIVE BE sheets of drawing. of the invention to of a Number Num Filed Ex	Its and Trademarks IS1 Inventor(s): MICHAEL H. FISHER, DONG OK SULFONAMIDES AS SELECTIVE BETA 3 AGO sheets of drawing. of the invention to of a INUMBER Number Filed Number Extra	Image: Signature Deposit Accl. 13-2755 MERCK & CO., INC. Our Case Docket No. 19 Image: Signature Our Case Docket No. 19 Image: Signature MICHAEL H. FISHER, DONG OK, ELIZABETH M. NAYLO SULFONAMIDES AS SELECTIVE BETA 3 AGONISTS FOR THE TREAT

Please charge my Deposit Account No. 13-2755 in the amount of \$ 710.00 . The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 13-2755. Duplicate copies of this sheet are enclosed.

TOTAL FILING FEE -



1.4.10.0.4

multiple dependent claims, regardless

REV.6/14/93

6 (64 m

of number.

IN TRIPLICATE

Respectfully,

By: Mollie Mr. Yeng

Attorney For Applicant(s)

Reg. No. 32,718 MERCK & CO., INC. Patent Dept. P.O. Box 2000 Rahway, N.J. 07065-0907 (908) 594- 6343

Date: April 26, 1994

APPROVED FOR LICENSE `®⁄233166 INITIALS MAY 1 8 94 9 Date Entered Date Received CONTENTS or Mailed ð _____ papers. 1. Application 8.5-94 7-21-94 2. KC 3. Prior art 7/29/94 4. Rey in Record 11/8/94 2.2.95 (i) tai 13/93 5 3/6/93-2/28/93 6. Smilt a 3-24-95 To Notice of altrademore 3129195 ABANDONED 2 AUS 1 7 1995 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. ÷ 20. 21. 22. 23. the 24. 25. 26. 27. 28. 29. 30. + 31. 32. (FRONT) Page 104 of 108

18 AM


	WU.S.B.P.O.: 19	94 - 378-972	Stimber Star		AL ANTI SA
PATENT NUMBER	GLASS 54		BIFICATION BELASS		
APPLICATION SERIAL NUMBER	1995年1月1日	CRO	SS AEFEREN	CE(S)	ALLES K. HERBER
08/233,166	CLASS	CLASS SUBCLASS IONE SUBCLASS PER BLOCK)			
APPLICANT'S NAME (PLEASE PRINT)	514	300	341	352	
Fiber et ql	546	17	276	311	3/2
F REIBSUE, ORIGINAL PATENT NUMBER	- 546	208			
INTERNATIONAL CLASSIFICATION		19 and the	1-		
CO7D 213/02	a creations				A Sale Ince In
A 6 1 K 31 X444	ARTUNIT	MARY EXAMINE	DAVIS	MARINT JULL NA	State & State of State


1.1

Staple Issue Slip Here

POSITION	id NO,	DATE
CLASSIFIER	1 1	5-184
EXAMINER	341	5/20/99
TYPIST	259	15-23MY
VERIFIER	342	5-2.5
CORPS CORR.	A SPECIAL PROPERTY OF	in the set
SPEC. HAND		
FILE MAINT.		
DRAFTING	State State State	


INDEX OF CLAIMS





(LEFT INSIDE)

SYMBULS



SEARCHED Date Exmr. Sub. Class 334072-7-2094 8KQ, 357,352-2094 8KQ, 34KL 200 596 SIA Search 40 Cate + 117, 21 320-95 mg 546 SEARCH NOTES Date Exmr. (15 Computer Scorth 1966-Jo Date 1-7.99 30 INTERFERENCE SEARCHED Sub. Class Exmr. Date SAME AS ABOVE 15 \$ 20-95 20 \$ Page 108 of 108 (RIGHT OUTSIDE)